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ABSTRACT 
Patients with essential hypertension have higher pain thresholds than individuals with normal 
blood pressure and may show evidence of subclinical peripheral neuropathy. Hypertension is 
strongly associated with diabetic neuropathy and the observed sensory loss may be aggravated by 
hypertension-induced nerve ischaemia and hypoxia. Two studies are presented in this thesis. 
First, 20 hypertensives and 25 normotensives had vibration, cooling, warming and heat-pain 
thresholds measured using the “CASE IV” system to assess evidence of subclinical peripheral 
neuropathy. Higher vibration thresholds were demonstrated in the feet of the hypertensives, 
which were significantly correlated with SBP and DBP. Conversely, a significant negative 
correlation between SBP and DBP with cooling and warming thresholds in the hand was found. 
Second, in a separate database analysis, cardiovascular risk, including metabolic profile and 
ambulatory arterial stiffness index, was compared in 83 confirmed and 154 borderline 
hypertensives. Cardiovascular risk factors of the borderline group suggested that these patients 
necessitate intervention with lifestyle measures at the very least. Further studies are needed to 
prove causality between hypertension and subclinical peripheral neuropathy. If such an 
association is found across all grades of hypertension, earlier intervention with antihypertensive 
medication might be appropriate, even in patients with low cardiovascular risk. 
-ii- 
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CHAPTER 1: INTRODUCTION AND AIMS 
1.1 Hypertension 
1.1.1 Background and Epidemiology  
Hypertension is defined as repeatedly raised clinic blood pressure (BP) ≥140/90 mmHg (Table 
1).
1-3
 Nearly 1 in 3 adults has high blood pressure and the prevalence of high blood pressure in 
England in 2007 was 31% among men and 29% among women.
4;5
 Hypertension is a highly 
prevalent risk factor for cardiovascular disease (CVD) throughout the developed world.
6
 
Cardiovascular disease [including coronary heart disease (CHD) and stroke] has been the most 
common cause of death in England and Wales for nearly a century in both males and females.
7
 
For example, in 2003 CHD caused 21.6% and 15.8% respectively of all male and female deaths; 
cerebrovascular disease was a close second.
8
 The World Health Organisation (WHO) estimates 
that high blood pressure related illness causes 1 in 8 deaths making hypertension the third leading 
killer in the world.
9
 Hypertension is therefore an important area of medical research. 
 
-2- 
1.1.2 Pathophysiology of Hypertension  
The pathophysiology of hypertension remains uncertain. Two to five percent of hypertensives 
have an underlying renal or adrenal cause for their raised blood pressure, known as secondary 
hypertension. However, the majority have no single identifiable cause and their condition is 
termed essential hypertension.
10
 Even though there are no direct causes for essential hypertension 
there are many risk factors that contribute towards its development the most important of which 
are: excess body weight, excess dietary sodium intake, reduced physical activity, inadequate 
intake of fruits and vegetables, and excess alcohol.
2
  
 
1.1.3 Grades of Hypertension 
Two major guidelines for the assessment and treatment of hypertension were published in 2003, 
from the European Society of Hypertension-European Society of Cardiology guidelines for the 
management of arterial hypertension (ESHC) and the Seventh report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 
7).
1;2
 The recommendations in the two guidelines are similar in some ways. However, the two 
guidelines classify blood pressure differently (Table 1). The ESHC guidelines grade hypertension 
as mild, moderate or severe, whereas the JNC 7 guidelines grade hypertension as either Stage 1 
or Stage 2. 
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Table 1. Classification of BP Levels (mmHg) in the ESHC and JNC 7 2003 Guidelines
1;2
 
ESHC JNC 7 
Category Systolic Diastolic Category Systolic Diastolic 
Optimal <120 <80 Normal <120 <80 
Normal 120-129 81-84 Prehypertension 120-139 80-89 
High-Normal 130-139 85-89    
Grade 1 HT (mild) 140-159 90-99 Stage 1 HT 140-159 90-99 
Grade 2 HT (moderate) 160-179 100-109 Stage 2 HT ≥160 ≥100 
Grade 3 HT (severe) ≥180 ≥110    
HT, Hypertension 
 
The British Hypertension Society  (BHS) IV classification of blood pressure equates to that of the 
ESHC and that of The World Health Organization/International Society of Hypertension 
(WHO/ISH),
11
 and is based on clinic blood pressure values [ABPM readings should be adjusted 
upwards (e.g. by 10/5mmHg)]. If systolic blood pressure and diastolic blood pressure fall into 
different categories, the higher value should be taken for classification.
1;3;11
  
 
1.1.4 Hypertension and Cardiovascular Disease Risk  
Increasing blood pressure has been shown to be positively correlated with risk of coronary heart 
disease (CHD) and stroke, together termed cardiovascular disease (CVD).
12
 However, the 
coexistence of other risk factors such as age, smoking and cholesterol have been shown to result 
in dramatic increases in CVD risk associated with any blood pressure level.
13;14
 Estimates of 
cardiovascular and/or coronary risk can be easily calculated using computer programmes or 
charts such as the risk prediction charts, which are located at the back of the British National 
Formulary (BNF). Some of these computer programmes/charts are derived from complex 
equations based on data from the Framingham Heart Study.
15
 The so-called, „Framingham 
-4- 
equation‟ has been shown to apply to Northern European populations including Britain, although 
it may not be applicable to all patient populations.
13;16
 The BHS IV guidelines base risk 
prediction on the Framingham equation as it is the only method of estimating the risk of 
cardiovascular morbidity and mortality in both men and women, which includes most of the risk 
factors routinely available to the clinician, including: 
- Age (years) 
- Female (1, woman; 0, man) 
- Systolic blood pressure (SBP) [average of 2 office measurements (mmHg)] 
- Diastolic blood pressure (DBP) [average of 2 office measurements (mmHg)] 
- Cholesterol [total serum cholesterol measured by the Abell-Kendall method (mg/dl)] 
- HDL cholesterol [determined after heparin-manganese precipitation (mg/dl)] 
- Smoking (1, cigarette smoking or quit within past year; 0, otherwise) 
- Diabetes [1, diabetes; 0, otherwise (conservative definition is treatment with insulin or 
oral agents or having a fasting glucose of 7.7mmol/L or above)] 
- ECG-LVH (1, definite; 0, otherwise).3;15 
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1.1.5 Hypertension Management 
The ESHC 2003, ESHC 2007, JNC 7 and BHS IV guidelines differ slightly when it comes to the 
management of hypertension. 
 
1.1.5.1 ESHC 2003 
The ESHC 2003 guidelines base the decision to initiate antihypertensive medication on the total 
level of cardiovascular risk (Table 2) as well as the level of systolic and diastolic blood pressure 
(Table 1).
1
  
 
Table 2. ESHC 2003 Guidelines for the Stratification of Cardiovascular Risk in Order to 
Quantify Prognosis
1
 
 Blood pressure (mmHg) 
Other risk factors and disease history Normal  
SBP 120-129 
or DBP 80-84 
High normal  
SBP 130-139 
or DBP 85-89 
Grade 1 HT 
SBP 140-159 
 or DBP 90-99 
Grade 2 HT 
SBP 160-179 
or DBP 100-109 
Grade 3 HT 
SBP ≥180 
or DBP ≥110 
No other risk factors Average risk Average risk Low 
added risk 
Moderate 
added risk 
High 
added risk 
1-2 risk factors Low 
added risk 
Low 
added risk 
Moderate 
added risk 
Moderate 
added risk 
Very high 
added risk 
≥3 risk factors or TOD or diabetes Moderate 
added risk 
High 
added risk 
High 
added risk 
High 
added risk 
Very high 
added risk 
ACC High 
added risk 
Very high 
added risk 
Very high 
added risk 
Very high 
added risk 
Very high 
added risk 
ACC, associated clinical conditions; TOD, target organ damage 
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According to the ESHC 2003 guidelines, if an individual has Grade 1 or 2 hypertension clinicians 
should: (i) assess other risk factors, target organ damage (TOD), diabetes, and associated clinical 
conditions (ACC), (ii) initiate lifestyle measures and correction of other risk factors or disease 
and (iii) stratify absolute risk (Table 2). If absolute risk is „very high‟ or „high‟ begin drug 
treatment promptly, if „moderate‟ monitor BP and other risk factors for at least 3 months. If after 
3 months SBP ≥140 mmHg or DBP ≥90 mmHg then begin drug treatment but if after 3 months 
SBP <140 mmHg and DBP <90 mmHg then continue to monitor. If absolute risk is „low‟ 
monitor BP and other risk factors for 3-12 months. If after 3-12 months SBP ≥140-159 mmHg or 
DBP ≥90-99 mmHg then consider drug treatment and elicit patient‟s preference but if after 3-12 
months SBP <140 mmHg and DBP <90 mmHg then continue to monitor.
1
 
 
If an individual has Grade 3 hypertension clinicians should: (i) begin drug treatment immediately, 
(ii) assess other risk factors, TOD, diabetes and ACC and (iii) add lifestyle measures and 
correction of other risk factors or disease.
1
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1.1.5.2 ESHC 2007 
The ESHC 2007 guidelines are very similar to the 2003 guidelines with respect to the 
management of Grade 1-3 hypertension. The differences in the most recent guidelines are: (i)  
individuals with Grade 1 hypertension with no other risk factors (low added risk) should practice 
lifestyle changes for several months (as opposed to 3-12 months) and then start drug treatment if 
BP remains uncontrolled, (ii) individuals with Grade 1 hypertension with 1-2 risk factors and 
individuals with Grade 2 hypertension with no other risk factors or 1-2 risk factors (moderate 
added risk) should practice lifestyle changes for several weeks (as opposed to at least 3 months) 
and then start drug treatment if BP remains uncontrolled.
17
 
 
1.1.5.3 JNC 7 
In contrast to the ESHC guidelines, the JNC 7 guidelines do not take cardiovascular risk or target 
organ damage into account when making treatment decisions. Rather, all individuals with Stage 1 
hypertension (SBP 140-159 mmHg or DBP 90-99 mmHg) or Stage 2 hypertension (SBP ≥160 
mmHg or DBP ≥100 mmHg) should initiate lifestyle modification and drug therapy.2 
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1.1.5.4 BHS IV 
The BHS IV guidelines recommend the following management of hypertension:  
- Provide lifestyle advice for all people with high BP and those with borderline (Grade 1) or 
high-normal BP. 
- Start drug therapy in all patients with sustained SBP ≥160 mmHg or sustained DBP ≥100 
mmHg despite non-pharmacological measures.  
- Drug treatment is also indicated in patients with sustained SBP 140-159 mmHg or DBP 
90-99 mmHg if TOD is present, or there is evidence of established CVD, or diabetes, or 
the 10-year CVD risk is ≥20%, according to the Joint British Societies CVD risk 
assessment programme/risk chart.
3
 
  
-9- 
1.2 High-Normal Blood Pressure/Prehypertension  
Normal blood pressure is 120-129/81-89 mmHg according to the 2003 ESHC guidelines or 
≤120/80 mmHg according to the JNC 7 guidelines (Table 1).1;2 Hypertension is defined as BP 
≥140/90 mmHg.1-3 There is a grey area in between these two thresholds where BP cannot be 
regarded as either normal or hypertensive. Such BP levels are now regarded as „high-normal‟ in 
Europe (130-139/85-89 mmHg) or „prehypertension‟ in the United States (US) (120-139/80-89 
mmHg) (Table 1).
1;2
 The latter has raised some controversy as it means that many people 
previously considered entirely normal according to ESHC guidelines will now be labeled with a 
medical condition. 
  
1.2.1 Prevalence of High-Normal BP/Prehypertension 
Data from the 1999 and 2000 National Health and Nutrition Examination Survey (NHANES III) 
estimated that the prevalence of prehypertension among adults in the US was approximately 
31%.
18;19
 The prevalence was higher among men than women (39% and 23% respectively) and 
higher in obese than normal weight individuals.
19;20
 NHANES 2005-2006 reported that an 
estimated 25% of the US population aged 20 years or older has prehypertension, including over 
32 million men and 21 million women.
21;22
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1.2.2 High Normal BP/Prehypertension and Rate of Progression to Hypertension 
Prehypertension is likely to progress to hypertension fairly rapidly in the absence of lifestyle 
changes, particularly in the elderly and in individuals whose blood pressures lie in the upper 
portion of the prehypertensive range i.e. 130-139/85-89 mmHg.
13
 Vasan RS et al., 2001 assessed 
the development of hypertension in normotensive participants in the Framingham Heart Study 
and found a stepwise increase across three non-hypertensive BP categories (optimal, normal and 
high-normal BP) over a period of four years (Table 3). This increase was more prominent in 
individuals aged 65-94 years compared to those aged 35-64 years.
23
 Similar findings were 
reported in the Trial of Preventing Hypertension (TROPHY) study where 63% of prehypertensive 
individuals (BP 130-139/85-89 mmHg) aged 30-65 years, receiving a placebo, developed 
hypertension over four years of follow-up.
24
 In 2008 Falkner B et al., found that among 
adolescents aged 13-17 years the progression from prehypertension to hypertension was 
significantly greater than the progression from normotension to hypertension. 15% of boys and 
14% of girls with prehypertension had hypertension four years later whereas only 5% of boys and 
6% of girls with normotension had hypertension four years later.
20
  
 
Table 3. Rate of Progression of Optimal, Normal and High-Normal BP to Hypertension (≥140/90 
mmHg) in Individuals Aged 35-64 Years and Those Aged 65-94 Years23 
 Optimal BP           
(<120/80 mmHg) 
Normal BP                          
(120-129/80-84 mmHg) 
High-Normal BP                
(130-139/85-89 mmHg) 
35-64 years old 5.3% 17.6% 37.3% 
65-94 years old 16% 25.5% 49.5% 
-11- 
1.2.3 Association of High-Normal BP/Prehypertension with Other CVD Risk Factors 
In a study of the 1999 to 2000 National Health and Nutrition Examination Survey (NHANES) III 
data, Greenlund et al., 2004 found that occurrence of CVD risk factors including: above-normal 
cholesterol levels, excess weight/obesity, and diabetes mellitus, were greater in individuals with 
prehypertension after adjusting for age, sex and ethnicity. Surprisingly, these individuals were 
less likely to smoke than their normotensive counterparts.
19
 Prehypertensives were 1.65 times 
more likely to have at least 1 other CVD risk factor than normotensives.
19
 Similarly, in the 
Women‟s Health Initiative, age, body mass index (BMI), and prevalence of diabetes mellitus and 
hypercholesterolaemia increased across blood pressure categories (normal, prehypertension and 
hypertension), whereas smoking decreased.
25
 In a study of the NHANES II and NHANES II 
Mortality Study, Mainous III et al., found that 90% of patients with prehypertension had other 
CVD risk factors.
26
  
 
Risk ratios for specific risk factors including obesity, dyslipidaemia, insulin resistance, metabolic 
syndrome, and diabetes are all greater in prehypertensives than normotensives but fewer in 
prehypertensives than hypertensives.
13;27-30
 Furthermore, microalbuminuria is more common in 
prehypertensives than normotensives as are abnormalities in circulating markers of inflammation, 
such as C-reactive proteins, interleukin 6, and tumour necrosis factor-.13;31-33  
 
In the studies referenced above, blood pressure was categorised according to the JNC 7 
guidelines i.e. individuals were classed as having prehypertension if they were not taking 
antihypertensive medication and if they had SBP 120-139 mmHg or DBP 80-89 mmHg.
2
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1.2.4 High-Normal BP/Prehypertension and Risk of Mortality or Developing CVD 
Prehypertension appears to be associated with an increased incidence of CVD, especially in those 
individuals with BP between 130-139/85-89 mmHg and/or a history of diabetes or glucose 
intolerance.
30;34-36
 Qureshi et al., 2005 examined existing data from the Framingham  study and 
found that a prehypertensive person is more than 3 times more likely to have a myocardial 
infarction and 1.7 times more likely to have heart disease than a person with normal BP: the risk 
of stroke was not increased.
37
 Similarly, in a different study, mortality from CVD was found to be 
significantly greater in prehypertensive than normotensive individuals but the differences 
disappeared once  adjustments were made for presence of other CVD risk factors.
26
  
 
In a longitudinal population-based, US cohort, prehypertension was associated with increased 
risk of major cardiovascular events (including stroke, myocardial infarction and heart failure) 
independently of other cardiovascular risk factors.
35
 These findings, along with the presence of 
cardiovascular risk factors in 93% of the participant sample, support recommendations for 
clinicians to actively target lifestyle modifications and multiple risk factor reduction in their 
prehypertensive patients.
35
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1.2.5 Treating High-Normal BP/Prehypertension with Lifestyle Approaches to Prevent 
Hypertension or CVD 
Dietary approaches, either alone or with other lifestyle modifications, have been shown to reduce 
blood pressure in prehypertensives as well as hypertensives.
38-42
 The results of the DASH 
(Dietary Approaches to Stop Hypertension) study in 1997 revealed that a diet rich in fruits, 
vegetables, and  low-fat dairy foods and with reduced saturated and total fat can substantially 
lower blood pressure, especially when implemented in conjunction with weight control (BMI 20-
25kg/m
2
), adequate potassium intake [>90mmol (2500mg) per day], low salt diet (<100mmol/day 
or <6g sodium/day or <2.4g sodium chloride/day) and limited alcohol consumption (no more 
than 3 units/day in men and no more than 2 units/day in women).
3;38;39;43
 Since 1997 it has 
become evident that a diet higher in protein and unsaturated fat and lower in carbohydrate can 
reduce blood pressure even further than the DASH diet alone.
3;40
 In addition, physical activity (30 
minutes 3-5 times each week) is known to reduce blood pressure further still.
3;44;45
 Interestingly, 
cigarette smoking, (except when chronic and heavy) does not appear to be associated with 
hypertension.
46;47
 However, smoking does increase risk of cardiovascular disease considerably, 
therefore smoking cessation is recommended.
3
  
 
Lifestyle changes can lower blood pressure in prehypertensives and thus reduce the likelihood of 
developing hypertension with its associated CVD risk (Table 4).
2;48
 Unfortunately, in order for 
lifestyle modifications to substantially lower blood pressure they need to be adhered to and 
sustained, which many people find difficult.
1
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Table 4. Lifestyle Interventions for Blood Pressure Reduction in Prehypertensives
48
 
Strategy Recommendation SBP Effect in 
Prehypertension 
Effect on Incidence of 
Prevalence of 
Hypertension 
DASH dietary pattern 4-5 fruits/day 
4-5 vegetables/day 
2-3 low-fat dairy/day 
<25% fat 
3.5 mmHg 
 
Decreased by 62% 
(prevalence) 
Weight loss Effective BP lowering 
even without attaining 
normal BMI 
1 mmHg/kg weight loss Decreased by 42% 
(incidence) 
Reduced sodium intake <2400 mg/day 2 mmHg per 76 mmol/L 
per day decrease 
Decreased by 38% 
(incidence) 
Physical activity Moderate exercise ≥30 
minutes most days 
3-4 mmHg Not Available 
Moderation of alcohol 
intake 
≤2 oz/day (men); ≤1 
oz/day (women) 
3.5 mmHg Not Available 
 
In order to prevent or delay the onset of hypertension in the population as a whole, a public health 
strategy that complements the hypertension treatment strategy is warranted.
2
 Such a strategy 
would require a multipronged approach directed to communities, schools, worksites, and the food 
industry.
2
 For example, in 2002 the American Public Health Association and the National High 
Blood Pressure Education Program Coordinating Committee recommended that the food 
industry, including manufacturers and restaurants, reduce sodium in the food supply by 50% over 
the next 10 years.
2
 More public health initiatives like this need to be implemented in order to 
reduce BP in the general population.
2
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As mentioned previously, Qureshi et al., 2005 found that prehypertension is associated with 
increased risk of myocardial infarction and coronary artery disease. This raises the question of 
whether we should treat prehypertensive patients more aggressively i.e. with antihypertensive 
medication.
37
  
 
1.2.6 Management of High-Normal BP/Prehypertension 
Unsurprisingly, there is much controversy about how individuals with high-normal 
BP/prehypertension should be managed.  
 
The JNC 7 guidelines focus on BP values as the main variables determining the need for 
treatment and the type of treatment.
17
 JNC 7 recommends that individuals with prehypertension 
(BP in the range 120-139/80-89 mmHg) should be firmly advised to practice lifestyle 
modification and those who also have diabetes or kidney disease should be considered for 
appropriate drug therapy if lifestyle modification fails to reduce their BP to 130/80 mmHg or 
less.
2
  
 
The ESHC guidelines emphasise the importance of overall (or global) cardiovascular risk 
assessment, rather than a strict focus on hypertension, when making treatment decisions.
1;17
 The 
ESHC guidelines recommend that people with high-normal BP (130-139/85-89 mmHg) that have 
average (no other risk factors) or low added (1-2 risk factors) cardiovascular risk should have no 
BP intervention or lifestyle changes, respectively.
1;17
 Individuals with high added cardiovascular 
risk (3 or more risk factors, metabolic syndrome, subclinical organ damage or diabetes) should 
initiate lifestyle changes and either consider drug treatment (if not diabetic) or start drug 
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treatment (if diabetic) and those with very high added cardiovascular risk (established 
cardiovascular or renal disease) should initiate lifestyle changes and start immediate drug 
treatment.
17
 The BHS IV guidelines differ from both JNC 7 and the European guidelines in that 
they do not mention intervention with antihypertensive medication at blood pressures 
<140/90mmHg.
3
 
 
1.2.7 Treating High-Normal BP/Prehypertension with Antihypertensive Medication to 
Prevent Hypertension or CVD 
A handful of trials have investigated the effects of antihypertensive medication in individuals 
with prehypertension/high normal blood pressure.  
 
The TROPHY trial was a large trial to assess the feasibility of treating prehypertension (130-
139/85-89 mmHg) with the angiotensin-receptor blocker candesartan in order to prevent or delay 
the onset of hypertension.
24
 Participants were randomised to receive two years of candesartan or 
placebo, followed by two years of placebo for both groups. After two years the blood pressure in 
the candesartan group decreased more rapidly than in the placebo group resulting in a relative 
risk reduction in the risk of new-onset hypertension of 66.3% in the candesartan group. After four 
years (two years after discontinuation of candesartan) blood pressure rose more rapidly in the 
candesartan group resulting in a relative risk reduction in the candesartan group of 15.6%. Thus, 
candesartan reduced blood pressure and delayed the onset of hypertension during treatment but 
the benefits were not sustained once treatment was withdrawn. Notably, rates of serious adverse 
events during candesartan treatment were low and were similar in the two groups.
24
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The Prevention of Hypertension with ACE-inhibitor Ramipril in Patients with High Normal 
Blood Pressure (PHARAO) trial investigated the capacity of ramipril (an angiotensin-converting 
enzyme inhibitor) to prevent or delay the onset of hypertension in patients with high-normal 
blood pressure.
49
 Hypertension and high-normal blood pressure were defined in accordance with 
JNC 7/ESHC.
1;2
 Participants were randomised to the ramipril treatment group or the control 
group. 30.7% of subjects in the ramipril group, and 42.9% in the control group developed 
hypertension over a period of three years. Treatment with ramipril significantly reduced the 
progression to hypertension by 34.4% compared with the control group. These results are in line 
with those of the TROPHY trial.
49
 Interestingly, multivariate analysis revealed that the risk of 
progression to hypertension rises by 5% with each mmHg of office SBP. Although a clear-cut fall 
in BP was observed in the initial treatment phase with ramipril, the subsequent BP difference 
between the two groups was minimal (SBP 1-2 mmHg lower in the ramipril group), suggesting 
that treatment of high-normal blood pressure with ramipril may not be beneficial in the long-
term. There was no difference in the frequency and type of adverse events between the treatment 
and control group. However, there was a higher incidence of cough in the ramipril group.
49
  
 
In 2007, Skov et al., performed a small study to investigating whether early treatment with an 
candesartan in young (18-20 years old) normotensive offspring of hypertensive parents 
persistently lowered blood pressure after treatment withdrawal. Participants were randomised to 
receive either candesartan or placebo. The intervention period was 12 months, with 24 months of 
follow-up. Findings of this study showed that although candesartan significantly reduced blood 
pressure, renal vascular resistance and left ventricular mass during treatment, at 12 and 24 
months follow-up mean ambulatory blood pressure monitoring (ABPM) was no different 
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between subjects who received candesartan and those who received a placebo. Thus, temporary 
treatment of subjects at high familial risk of future hypertension with an angiotensin receptor 
blocker is feasible, but the treatment had no persistent effect on blood pressure when treatment 
was withdrawn. There were no significant differences in adverse events between the two 
groups.
50
  
 
It might be difficult to know if long term antihypertensive therapy in pre-hypertensive patients 
has any effect. In addition, it is difficult to justify treatment with antihypertensive drugs that may 
result in adverse events and will have considerable cost implications. Further outcome trials are 
needed to determine i) the effects of pharmacological treatment on target organ damage and 
cardiovascular morbidity and mortality ii) whether they are safe when administered over many 
decades, as would be required to treat young individuals with prehypertension and iii) whether 
they are cost-effective for the treatment of patients with such low absolute risk of CVD.
22
 In the 
meantime a more attractive strategy would be to improve lifestyle in the population for example 
by reducing “hidden” salts in processed foods such as bread (1 slice contains 0.5g of salt), 
breakfast cereals, ready-made meals and flavour enhancers such as stock cubes or manufactured 
sauces to reduce daily intake to <6 g.
3
 Other population-based strategies might be to increase 
attention to health education by general practitioners, increase access to places to engage in 
physical activity, reduce servings of food in restaurants, increase availability of healthy food 
choices in schools, worksites and restaurants, increase exercise programs in schools and decrease 
the cost of low-sodium/low calorie food products.
2
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In summary, available guidelines recognise that high-normal or pre-hypertension may progress to 
established hypertension and is associated with an increased risk of cardiovascular disease. The 
management advice differs depending on the guidelines used but mostly suggests that lifestyle 
intervention is appropriate to reduce blood pressure. More accurate ways of establishing which 
individuals are at risk of developing cardiovascular disease include standard risk assessment as 
well as novel methods outlined in the next section. 
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1.3 Additional Ways to Assess Cardiovascular Risk  
1.3.1 Arterial Stiffness 
1.3.1.1 Definition and Mechanisms Underlying Arterial Stiffness 
Arterial stiffness (arteriosclerosis) refers to stiffening of the arteries, particularly the more 
compliant and distensible central arteries e.g. the aorta and its branches.
51
 Arterial stiffening 
occurs due to a complex interaction between stable and dynamic changes involving structural 
(e.g. collagen and elastin) and cellular elements (e.g. endothelial cell signalling and vascular 
smooth muscle cell tone) of the vessel wall.
52
 For example, stimulation of an inflammatory 
environment causes overproduction of abnormal, cross-linked collagen and diminished quantities 
of normal elastin in the vessel wall, increasing arterial stiffness. These vascular alterations i.e. 
changes in the extracellular matrix and endothelial cell dysfunction, are influenced by 
haemodynamic forces such as shear stress and mechanical stretch as well as by “extrinsic factors” 
such as hormones (e.g. angiotensin II and aldosterone), advanced glycation end products (AGEs), 
chronic inflammation, vascular calcification, high sodium intake, and glucose regulation (Figure 
1).
52;53
 Aging is the dominant process altering vascular stiffness.
51
 However, diseases such as 
hypertension, diabetes mellitus and chronic kidney disease amplify the vascular changes that 
result in arterial stiffening.
52;53
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Figure 1. Summary of the Multiple Causes and Locations of Arterial Stiffness
52
 
AGE‟s, advanced glycation end products; MΦ, MMP-7 (an elastase); I-CAM, Inter-Cellular Adhesion Molecule; 
MMP, matrix metalloproteases; TGF-β, transforming growth factor; VSMC, vascular smooth muscle cell; NaCl, 
sodium chloride 
 
1.3.1.2 Arterial Stiffness and Cardiovascular Risk 
Arterial stiffening increases systolic blood pressure and pulse pressure causing myocyte 
hypertrophy, increased left ventricular after load and reduced coronary perfusion, resulting in 
diastolic and systolic dysfunction and ultimately congestive heart failure.
53
 Raised systolic and 
pulse pressures also promote further vascular damage increasing risk of stroke and progressive 
loss of kidney function (Figure 2).
53
  
 
It is now well accepted that aortic stiffness is an intermediate endpoint for cardiovascular events, 
either fatal or non-fatal.
54
 In addition, large-artery stiffness has proved to be an independent 
predictor of adverse cardiovascular outcomes in the general population as well as in patients with 
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primary hypertension, diabetes, or end-stage renal disease.
55
 Its prognostic value has been shown 
to extend even beyond classic cardiovascular risk factors entering various types of risk score.
54;55
 
Arterial stiffness is therefore important, not only for assessing cardiovascular risk but also for 
predicting cardiovascular outcomes.
54
 Arterial stiffening also provides direct evidence of target 
organ damage, which is of major importance in determining the overall cardiovascular risk of 
hypertensive patients.
54
 Arterial stiffness should therefore be considered as a recommended test 
for the evaluation of cardiovascular risk, particularly in patients in whom target organ damage is 
not discovered by routine investigations.
54
 With this in mind it is important to be able to measure 
arterial stiffness accurately and easily in order to predict an individual‟s cardiovascular risk. 
However, the widespread measurement of arterial stiffness in clinical practice is limited by the 
need for specific technical equipment and trained personnel.
55;56
 
 
 
Figure 2. Consequences of Increased Arterial Stiffness
53
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1.3.1.3 Methods of Measuring Arterial Stiffness 
Non-invasive measures of arterial stiffness fall into three broad groups: i) measuring pulse wave 
velocity (PWV), ii) using ultrasound to relate the change in diameter (or area) of an artery to 
distending pressure in order to measure arterial distensibility/compliance, and iii) assessing 
peripheral arterial pressure waveforms (e.g. augmentation index [AIx]) by applanation 
tonometry.
57;58
  
 
The most common method for evaluating arterial stiffness is based on the study of PWV i.e. the 
velocity of the BP propagation wave along a given conduit artery, for example, the aorta.
59
  
Measurements involve applanation tonometry, mechanotransducer or Doppler probes and are 
regarded as the gold standard for determining arterial stiffness, independent of wave activity: the 
higher PWV, the higher arterial stiffness.
59
 In parallel, the technique of applanation tonometry is 
widely used to evaluate central pressure and mostly wave reflections through the non-invasive 
use of the parameter called augmentation index (AIx). AIx is an indirect measure of carotid 
stiffness, but mainly a direct measure of central wave reflection.
59
 
 
There are many commercial devices available that use different methods to measure arterial 
stiffness.
57
 Unfortunately, these devices can be expensive and are often complicated to use and 
are thus operator-dependent. This means measurement of arterial stiffness cannot be performed 
easily in daily clinical practice. Consequently, there is a need for a more simple measure of 
arterial stiffness, which may have recently been identified in the form of the ambulatory arterial 
stiffness index (AASI). 
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1.3.1.3.1 Ambulatory Arterial Stiffness Index (AASI) 
The Ambulatory Arterial Stiffness Index (AASI) is a new, easy-to-obtain index of arterial 
stiffness.
55;56
 Ambulatory arterial stiffness index has been shown to strongly correlate with classic 
measures of arterial stiffness, such as PWV and AIx, and has been identified as an independent 
marker for target organ damage, cognitive function and cardiovascular and renal outcomes.
60
 
 
AASI is derived from 24-hour ABPM recordings. The theory behind this method is that the 
dynamic relation between diastolic and systolic blood pressure over 24 hours provides insight 
into the stiffness of the arterial wall.
61
 The regression slope of diastolic against systolic blood 
pressure is calculated and AASI is defined as 1 minus the regression slope (Figure 3). The stiffer 
the arterial tree, the closer the regression slope and AASI are to 0 and 1 respectively.
61
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Figure 3. Scatter Graph Showing 24-hour SBP Readings (x) Plotted Against 24-hour DBP 
Readings (y). The regression slope of diastolic against systolic blood pressure is calculated and 
AASI is defined as 1 minus the regression slope. 
 
Mean 24-hour BP (mmHg): 150/89 
Regression Slope: 0.77 units 
AASI: 0.23 units 
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1.3.2 Metabolic Syndrome 
Metabolic syndrome is the name given to a cluster of closely related cardiovascular risk factors 
namely: visceral obesity, dyslipidaemia, hyperglycaemia, and hypertension.
62
 The most recent 
diagnostic criteria for metabolic syndrome, from the International Diabetes Federation (IDF) is: 
central obesity (waist circumference ≥94 cm in males, ≥80cm in females or BMI >30 kg/m2 ) plus 
any two of the following four factors: raised triglycerides (≥1.7 mmol/L or specific treatment for 
this lipid abnormality), reduced HDL cholesterol (<1.03 mmol/L in males, <1.29 mmol/L in 
females or specific treatment for this lipid abnormality), raised blood pressure (SBP ≥130 mmHg 
or DBP ≥85 mmHg or treatment of previously diagnosed hypertension) and/or raised fasting 
plasma glucose (FPG ≥5.6 mmol/L, or previously diagnosed type II diabetes).62  
 
The cause of metabolic syndrome is unknown, which leads some people to question whether it is 
a syndrome at all. However, it remains useful to be able to identify individuals with metabolic 
syndrome because it is a risk factor for both cardiovascular disease and diabetes mellitus. In 
2005, the population-attributable fraction due to the metabolic syndrome, [as defined by the 
National Cholesterol Education Program (NCEP) and WHO] was found to be ~12-17% for CVD 
and ~30-52% for diabetes.
63
 More recently, Lorenzo et al., 2007 found that the IDF definition of 
metabolic syndrome predicted incident CVD risk (OR 1.69 [95% CI 1.13-2.54]) and diabetes risk 
(OR 5.76 [95% CI 4.11-9.07]) independently of other risk factors.
64
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1.4 Peripheral Neuropathy 
Hypertension is associated with reduced ability to feel pain, and there is some evidence that 
hypertensive individuals may have peripheral neuropathy.
65-71
 
 
Peripheral neuropathy infers damage or central inhibition of impulses to nerves of the peripheral 
nervous system (PNS). The PNS consists of the nerves that lie outside the central nervous system 
(the brain and spinal cord) and that innervate the limbs and organs. The PNS is divided into the 
somatic nervous system (voluntary) and the autonomic nervous system (involuntary). Population 
prevalence of peripheral neuropathy is around 2.4%, rising with age to 8%.
72
 There are many 
causes of peripheral neuropathy. The most common causes are diabetes mellitus, alcohol, certain 
drugs, and infections such as HIV (human immunodeficiency virus). Diabetes mellitus is the 
most common cause of peripheral neuropathy in the western world with a prevalence of 22.7% in 
Type I diabetics and 32% in Type II diabetics in the UK.
73;74
 Patients with peripheral neuropathy 
may experience altered sensation, pain, weakness or autonomic symptoms.
72
 Clinical features 
vary widely depending on the nerves affected, class and level of axon affected, age of onset, rate, 
course and severity of the pathologic process and degree of regeneration and sprouting, among 
other factors.
75
 The symptoms typically begin distally in the toes and fingers. They commonly 
appear in the toes before the fingers and spread proximally.
72
 Peripheral neuropathy is a long-
term, degenerative, disabling condition for which there is currently no treatment other than 
symptomatic relief, therefore research in this area is paramount. 
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It is known that hypertension is strongly associated with the development of diabetic neuropathy 
(a form of peripheral neuropathy specific to diabetes) and that unmedicated hypertensives have 
higher pain thresholds than normotensives.
65;66;76-84
 These findings lead us to hypothesise that 
hypertension may be associated with peripheral neuropathy i.e. increased thresholds of other 
sensory modalities as well as pain, and that this sensory loss may be a direct result of 
hypertension even when diabetes is not present. 
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1.5 Hypertension and Diabetic Neuropathy  
A link between peripheral neuropathy and hypertension can be seen in diabetes mellitus where 
many studies have found hypertension to be strongly associated with the development of diabetic 
neuropathy. Diabetic neuropathy is a multifactorial process but hypertension has been found to be 
the most important predisposing cardiovascular risk factor.
76-81
 Harris et al., 1993 in a cross-
sectional study, concluded that hypertension and hyperglycaemia predispose to symptoms of 
sensory neuropathy. In logistic regression, factors independently related to symptoms of sensory 
neuropathy in people with Type II diabetes included duration of diabetes, hypertension, 
hyperglycaemia and glycosuria. In fact, hypertension was associated with a 60% higher 
likelihood of symptoms.
76
  Forrest et al., 1997 in a prospective cohort study, found that 
hypertension had the greatest impact on the development of distal symmetrical sensory 
polyneuropathy (DSSP) (the most common type of diabetic neuropathy) in individuals with both 
short or long-term Type I diabetes.
77
 Cohen et al., 1998 analysed data from The Appropriate 
Blood Pressure Control in Diabetes (ABCD) Trial (a cross-sectional study) and found that 
diabetic sensory peripheral neuropathy is independently associated with diabetes duration, body 
weight, age, retinopathy, overt albuminuria, height, duration of hypertension, insulin use, and 
race/ethnicity.
78
 More recently Tesfaye et al., 2005 in a prospective cohort study, demonstrated 
that in addition to glycaemic control, the incidence of neuropathy is associated with potentially 
modifiable cardiovascular risk factors, including raised triglyceride levels, body mass index, 
smoking and hypertension.
79
 Jarmuzewska et al., 2005 in a cross-sectional study, concluded that 
pulse pressure (an indicator of arterial stiffness) is independently and negatively associated with 
nerve function i.e. as pulse pressure increases, nerve function decreases, and in a subsequent 
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cross-sectional study in 2007 concluded that there is a strong association between hypertension 
and development of SMPN (sensorimotor peripheral neuropathy) in patients with relatively short-
term Type II diabetes.
80;81
 More recently, Balducci et al., 2006 found that long-term aerobic 
exercise training can prevent or modify the natural history of diabetic peripheral neuropathy. 
Interestingly, systolic and diastolic blood pressure in the exercise group decreased by 4 mmHg 
and 5 mmHg respectively over four years, potentially providing further evidence for a role of 
blood pressure in diabetic neuropathy.
82
  
 
The foregoing studies indicate that hypertension is a risk factor for diabetic neuropathy. The 
precise mechanisms underlying the development of diabetic neuropathy are unknown. Studies 
have found reduced nerve oxygenation and impaired blood flow in human diabetic neuropathy 
suggesting a key role for microvascular disease in its pathogenesis.
85;86
 There is evidence that 
diabetes-induced metabolic and vascular disturbances lead to abnormalities in the peripheral 
nerve microvasculature.
87
 These abnormalities are thought to cause ischaemia and hypoxia in 
peripheral nerves, causing peripheral nerve damage, resulting in peripheral neuropathy.
88
 
Ischaemia from peripheral vascular disease (PVD), (for which hypertension is a risk factor) 
brings about oxidative stress and injury to nerves via increased production of reactive oxygen 
species (ROS) as reinforced by the finding that glutathione (a free radical scavenger) can be 
partially effective at preventing experimental diabetic neuropathy, possibly by improving 
oxygenation.
89-91
 In this context, hypertension may contribute to the peripheral nerve damage 
seen in diabetic neuropathy. Interestingly, there is evidence of greater degrees of neuronal 
function impairment in painless than in painful neuropathy, with nerve blood flow impaired to a 
greater extent and oxygen saturation lower in individuals with painless than those with painful 
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neuropathy.
92;93
 Acute painful neuropathy occurring in the setting of normalisation of glycaemia 
may be associated with new vessel formation on the surface of the nerve, further suggesting 
important differences between painful and painless neuropathy.
92
 
 
In experimental studies on diabetic rats, antihypertensive agents have been shown to improve 
oxygenation, nerve blood flow, nerve abnormalities and nerve conduction as well as preventing 
nerve damage and dysfunction.
94-98
 Similarly, in studies of human diabetes, antihypertensives 
have been found to significantly improve motor and sensory nerve conduction velocity, warming 
and vibratory detection thresholds and diabetic neuropathy.
99;100
 These findings reinforce the 
possible deleterious effects of hypertension on peripheral nerve function in diabetics.  
 
Hypertension may be a risk factor for peripheral neuropathy, even in the absence of diabetes, a 
postulation that has been supported in a number of studies on spontaneously hypertensive rats 
(SHR). These studies demonstrated impaired vascular supply to peripheral nerves and 
morphological changes and decreased nerve function in the sciatic nerve, all of which were 
improved with antihypertensive medication.
101-103
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1.6 Hypertension and Hypoalgesia  
For nearly 30 years researchers have demonstrated that there is an association between decreased 
perception of pain (hypoalgesia) and hypertension. However, the mechanisms involved in this 
relationship are poorly understood.
104
 There is still doubt as to whether, in human essential 
hypertension, hypoalgesia is secondary to raised blood pressure or whether both depend on some 
common mechanism.
105
 Another uncertainty is whether there is a central cause for the 
hypoalgesia or damage to the peripheral nerves themselves. Based on the existing evidence, the 
baroreceptor reflex may coordinate cardiovascular and pain regulatory responses and opioid 
peptides may also be implicated. 
 
Activation of baroreceptor afferents via increases in blood pressure may play an important part in 
hypertension-associated hypoalgesia. This relationship can be observed in numerous 
experimental studies on hypertensive rats, in which hypoalgesia is brought about by baroreceptor 
activation and can be alleviated by carotid sinus baroreceptor denervation or by decreasing the 
cardiopulmonary baroreceptor afferent input.
106
 In addition, resection of the right cervical vagus, 
which reduces cardiopulmonary vasoreceptor afferent input, has been shown to markedly reduce 
hypoalgesic behaviour in SHR.
66
 It has been postulated that cardiovascular and pain regulatory 
responses may be coordinated as part of an adaptive mechanism, helping the body to face 
stressful events.
83;107  
 
A role for endogenous opioids in hypertension-associated hypoalgesia is suggested as a result of 
the finding that, in rats, this type of hypoalgesia is successfully suppressed by the opiate 
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antagonist naloxone. Furthermore, hypertensive rats were found to have increased opioid activity 
in several areas of the central nervous system (CNS).
66;105
 Interestingly, in a study on humans 
Ring et al., 2008 observed that hypertensives experienced less pain than normotensives during 
their assessment of pain tolerance but that this manifestation of hypertensive hypoalgesia was not 
moderated by naltrexone.
108
 
 
The existence of an association between increased arterial blood pressure and hypoalgesia has 
been repeatedly shown in experimental hypertension and confirmed in humans using various 
form of noxious stimuli, including electrical tooth pulp, thermal and electrocutaneous 
stimulation. Induction of hypertension in rats by different methods (mineralocorticoid treatment, 
phenylephrine administration, occlusion of abdominal aorta, renal artery clipping, 
deoxycorticoesterone acetate salt administration, social deprivation and hypothalamic grafts from 
SHR) is associated with reduced responsiveness to noxious stimuli (hot-plate, electric shock and 
mechanical force applied to a limb).
66;105;107
 The interaction between hypertension and pain 
perception has also been supported by the finding that experimental interventions acting to lower 
blood pressure also reduce hypoalgesia.
107
 
 
Increased tolerance to pain has also been observed in hypertensive humans. The first to report on 
hypertension-associated hypoalgesia in humans were Zamir and Shuber, 1980 who found a 
higher pain threshold during non-invasive tooth pulp stimulation in unmedicated essential 
hypertensives compared with normotensives.
65
 These results were confirmed using the same 
technique by Ghione et al., in 1988.
109
 Sheps et al., 1992 found that the average mean arterial 
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pressure in all participants (hypertensives and normotensives) was significantly related to both 
thermal pain threshold and tolerance.
84
 
 
More recently, Rosa et al., 1994 found significantly higher electrocutaneous perceptive, pain and 
tolerance thresholds in hypertensives compared with normotensives as well as significantly 
higher tooth pulp pain and tolerance thresholds.
66
 In addition, the thresholds of two components 
(R2 and R3) of the blink reflex to electrical stimulation of the supraorbitalis nerve were 
significantly higher in hypertensives and a significant correlation was found between R3 
threshold (nociceptive component of the blink reflex) and diastolic pressure. Together, these 
results confirm that hypertension is associated with hypoalgesia in humans.
66
 Even among 
normotensive humans, resting systolic blood pressure has been found to correlate negatively with 
pain ratings and in addition, normotensives at risk for developing hypertension have 
demonstrated decreased pain sensitivity compared with low risk individuals.
110
 
 
From a clinical perspective, hypertension-associated hypoalgesia is important since there is 
evidence that asymptomatic (silent) myocardial ischemia and unrecognised, presumably painless, 
myocardial infarction are more common in people with elevated blood pressure.
66;105;111
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1.7 Hypertension and Peripheral Neuropathy  
There have been few studies investigating the relationship between hypertension and peripheral 
neuropathy. The results of these have been inconclusive but some have shown a possible positive 
association between the two variables. 
 
Zamir and Shuber, 1980 found that sensory threshold as well as pain thresholds differed between 
normotensive and hypertensive subjects.
65
 Rosa et al., 1994 observed that other thresholds, which 
cannot easily be related to pain sensation (i.e. perceptive cutaneous threshold and the R2 
component of the blink reflex), are significantly increased in human hypertension. These findings 
may suggest that other sensations besides pain are reduced in arterial hypertension, but this 
proposal warrants further investigation.
66
 Zarrelli et al., 2001 concluded that arterial hypertension 
might be an independent risk factor for chronic symmetric polyneuropathy (CSP) in the elderly.
67
 
Legrady et al., 2006 found higher current perception threshold (CPT) values in the peroneal 
nerve of both diabetic and non-diabetic hypertensives compared to controls, indicating sensory 
loss. Duration of hypertension and diabetes mellitus both correlated positively with CPT's 
measured on the lower extremities in the diabetic hypertensive group. This study concluded that 
the severity of peripheral sensory neuropathy (PSN) was similar in non-diabetic and diabetic 
hypertensive patients although, in the latter, the PSN can involve more types of nerve fibres. 
Hypertension should thus be considered in the pathogenesis of peripheral nerve dysfunction.
68
 
 
Rivero Luis et al., 2006 found that peripheral and autonomic nerve function are often altered in 
obese people without diabetes and thus hypertension might contribute to peripheral nerve 
-36- 
dysfunction.
69
 Edwards et al., 2008 found that although hypertension did not affect sensory nerve 
conduction velocity, unmedicated essential hypertensives demonstrated sensory loss and 
significantly lower amplitude sensory nerve action potentials compared to normotensives.
70
 
These preliminary findings suggest that unmedicated hypertensives may have a reduced number 
of active nerve fibres, possibly resulting in mild subclinical peripheral neuropathy.
70
 In a 
subsequent study investigating the effects of essential hypertension on short latency human 
somatosensory-evoked potentials, Edwards et al., 2010 found unaltered peripheral nerve 
conduction velocities but reduced amplitude sensory nerve action potentials in unmedicated 
hypertensives compared to nomortensives, thus reinforcing their earlier findings and 
demonstrating that hypertension may affect the peripheral nervous system by causing axonal loss 
without affecting myelination.
71
 Results from these two recent studies oppose those of Viskoper 
et al., 1971 who showed reduced motor nerve conduction velocities in the upper extremities of  
medicated hypertensives compared to normotensives and that conduction velocities were 
inversely related to diastolic blood pressure.
112
  
 
The foregoing studies suggest that essential hypertension is characterised by sensory loss. 
However, the mechanisms underlying these sensory deficits remain unclear. The pathological 
process may be similar to that in diabetic neuropathy, whereby metabolic and vascular 
disturbances lead to structural and functional changes in blood vessels supplying the peripheral 
nerves, resulting in ischaemia and hypoxia and ultimately peripheral neuropathy.
87;88;101-103
 This 
is feasible since hypertension is a risk factor for peripheral vascular disease, which causes 
ischaemia leading to oxidative stress and injury to nerves via increase production of reactive 
oxygen species.
89-91
 In fact, studies on non-diabetic spontaneously hypertensive rats have 
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demonstrated impaired vascular supply to peripheral nerves and morphological changes and 
decreased nerve function in the sciatic nerve, all of which improved with antihypertensive 
medication.
101-103
 Furthermore, peripheral nerves are susceptible to ischaemia and hypoxia 
because they lack the ability to autoregulate (maintain a constant blood flow despite changes in 
perfusion pressure). Thus, they rely on a profuse blood supply to maintain oxygenation.
113
  
 
In sum, hypertension is a known risk factor for diabetic neuropathy and unmedicated essential 
hypertensives have a reduced ability to feel pain compared to normotensives. There is also some 
evidence that hypertension may cause peripheral neuropathy. However, the mechanisms 
underlying these associations remain unclear.  
-38- 
1.8 Hypotheses 
Two studies are presented in this thesis: 
1.8.1 Study One: Peripheral Neuropathy in Hypertension 
The evidence suggests an association between hypertension and peripheral neuropathy. It was 
therefore hypothesised that individuals with newly diagnosed unmedicated essential hypertension 
would show more sensory deficits in response to peripheral nerve stimulation than individuals 
with normal blood pressure. 
 
1.8.2 Study Two: Retrospective Database Analysis of Cardiovascular Risk in Confirmed 
and Borderline Hypertensive Patients  
Patients with hypertension often have other risk factors for cardiovascular disease which help 
clinicians decide whether to treat them with antihypertensive medications and/or lifestyle 
interventions. Cardiovascular risk profiles of patients with unmedicated confirmed hypertension 
or unmedicated borderline hypertension, selected from our Hypertension Database, were 
determined. It was hypothesised that the borderline hypertensives, who would not normally be 
started on antihypertensive medication in the absence of other risk factors, would have similar 
cardiovascular risk profiles to the confirmed hypertensives. 
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1.9 Aims 
1.9.1 Study One: Peripheral Neuropathy in Hypertension 
The primary aim of this thesis was to look at the influence of unmedicated essential hypertension 
(SBP ≥140 or DBP ≥90 mmHg) on a range of sensory thresholds to investigate the possibility 
that hypertension may cause subclinical peripheral neuropathy.  
 
1.9.2 Study Two: Retrospective Database Analysis of Cardiovascular Risk in Confirmed 
and Borderline Hypertensive Patients 
The secondary aim of this thesis was to compare cardiovascular risk factors, including 
ambulatory arterial stiffness index (AASI) and features consistent with the metabolic syndrome, 
in a larger number of patients with unmedicated confirmed hypertension (SBP ≥160 mmHg or 
DBP ≥100 mmHg) or unmedicated borderline hypertension (SBP 140-159 mmHg or DBP 90-99 
mmHg), selected from our Hypertension Database.  
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CHAPTER 2: STUDY ONE - PERIPHERAL NEUROPATHY IN 
HYPERTENSION 
2.1 Introduction and Aims 
It is known that hypertension is strongly associated with the development of diabetic neuropathy 
and that unmedicated hypertensives have higher pain thresholds than normotensives. There is 
also some evidence that hypertension may be positively associated with peripheral neuropathy. 
The present study will look at the influence of newly diagnosed unmedicated essential 
hypertension on a range of sensory thresholds (not just heat-pain) to investigate the possibility 
that hypertension may cause subclinical peripheral neuropathy across an array of sensory 
modalities. 
 
To our knowledge, no previous study has examined peripheral nerve function using a range of 
quantitative sensory tests, to assess a range of sensory nerve fibres and modalities in the upper 
and lower limbs of newly diagnosed unmedicated essential hypertensives.   
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2.2 Methods and Analysis 
2.2.1 Participants 
20 newly diagnosed unmedicated essential hypertensives (12 men, 8 women) and 25 
normotensive controls (9 men, 16 women) were investigated for subclinical peripheral 
neuropathy. Table 5 and 6 show the characteristics of the participants in the hypertensive and 
normotensive groups. Newly diagnosed unmedicated essential hypertensives (SBP ≥140 or DBP 
≥90 mmHg) were recruited from a hypertension clinic at the Wellcome Trust Clinical Research 
Facility (WTCRF), Queen Elizabeth Hospital (QEH), Birmingham, United Kingdom. 
Normotensive controls were recruited via email-sent out to all Queen Elizabeth and Selly Oak 
Hospital staff. Controls were paid £15 for their time. Participants gave written consent after 
reading an information sheet explaining the procedures involved. The local ethics advisory 
committee approved this study.  
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2.2.2 Establishment of Blood Pressure Status 
Patients with newly diagnosed unmedicated essential hypertension were recruited from a 
hypertension clinic. All patients underwent 24-hour ambulatory blood pressure monitoring 
(ABPM) (SpaceLabs, Model 90217) and 3 clinic BP measurements taken with an OMRON Mi-5. 
These monitors have been validated according to the protocols of the Association for the 
Advancement of Medical Instrumentation and the British Hypertension Society. Account was 
taken of the differences between ABPM measurements and clinic measurements as per BHS IV 
guidelines.
3
 Hypertension was defined as sustained systolic blood pressure at referral of 
≥140mmHg or a diastolic blood pressure of ≥90mmHg, which was confirmed at clinic and on 
ABPM. Normal blood pressure was defined as mean clinic blood pressure, on the day of 
testing, of <140mmHg systolic and <90mmHg diastolic.  
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2.2.3 Exclusion Criteria 
Participants were excluded for the following:  
 Age younger than 18 years or older than 50 years (the latter were excluded because there 
is evidence that risk of peripheral neuropathy increases with age).
114;115
 
 BP >180/110mmHg confirmed on ABPM with or without evidence of accelerated phase 
hypertension (blood pressure must be treated without delay) 
 Pregnancy or  menstrual period over 1 month ago 
 Major psychiatric disorder 
 Current use of prescription medication (excluding contraceptives) 
 Excess alcohol intake (>21 units/week in men, or >14 units/week in women) 
 Thyroid disease 
 Chronic liver disease 
 Cerebrovascular disease 
 Angina 
 Myocardial infarction 
 Peripheral vascular disease 
 Chronic neurological disease 
 Rheumatoid or osteoarthritis 
 Acromegaly or gout 
 Any chronic disease or any condition predisposing to carpal tunnel syndrome or 
peripheral neuropathy including diabetes mellitus (either pre-existing or diagnosed on 
random blood sugar sample) 
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 Other causes of peripheral neuropathy (hereditary neuropathy, B12 deficiency, 
cryoglobulinaemia etc.) 
 Neck or back surgery 
 Cardiac pacemaker 
 Consumption of alcoholic or caffeinated drinks 2 hours before the start of the study. 
 
If clinically indicated the patients in the hypertensive group had appropriate investigations to 
exclude secondary causes of hypertension before taking part in the study. On the basis of these 
investigations patients were excluded if there was evidence of underlying renal or adrenal 
pathology including acute or chronic renal failure, renal artery stenosis, glomerulonephritis, 
pyelonephritis, Conn‟s syndrome, or phaeochromocytoma. Any person with a poor understanding 
of English was also excluded from the study to ensure that informed consent was obtained and 
that tasks were followed correctly.  
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2.2.4 Apparatus and Physiological Measurements 
Height (m), weight (kg), waist (cm) and hip (cm) measurements were determined using standard 
methods. Blood pressure measurements were taken at rest in an upright sitting position. Systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) were obtained using an oscillometric 
sphygmomanometer and brachial cuff (Omron IC, Omron Health Care Ltd.) attached to the 
participant‟s upper right arm (the right arm was used for logistical reasons). Three consecutive 
readings were obtained before starting the sensory tests. These three readings were averaged to 
give measures of mean resting systolic and diastolic pressure. The following sensory nerve 
function tests and database analyses then commenced. 
 
2.2.5 Computer Aided Sensory Evaluator (CASE) IV 
The CASE IV system (WR Medical Electronic Co., USA) attached to a laptop (Toshiba) was 
used to administer stimuli and record threshold data. This system has been shown to be useful in 
conjunction with clinical examination for diagnosing diabetic neuropathy.
116
 
 
For vibration, cooling, warming and heat-pain detection thresholds, a cue device (WR Medical 
Electronics Co., USA) was used to denote the time period in which the stimuli were 
administered. For all these tests, except heat-pain, a response device (WR Medical Electronics 
Co., USA) with buttons marked „yes‟ and „no‟ was used to register the participant‟s response.  
 
Vibration detection threshold was measured using a vibration stimulator (WR Medical 
Electronics Co., USA). The vibration stimulator was placed on the participant‟s right index finger 
or big toe, in the midline between the base of the nail and the most distal knuckle (Figure 4). 
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Vibration was delivered at 125 cycles per second and was variable between 0 and 576 
micrometers.  
 
Thermal sensation and heat-pain detection thresholds were measured using a thermal stimulator 
(WR Medical Electronics Co., USA). The thermal stimulator was strapped to the dorsal surface 
of the participant‟s right hand or foot (Figure 5). During operation the thermal stimulator 
produced a specified temperature on a 9.0-square-centimeter stimulating surface. The stimulating 
surface temperature could be varied from 8.0°C to 50.0°C with accuracy of 1.25°C to 0.25°C 
depending on the temperature. 
 
Participants sat upright in a chair. During the sensory threshold assessment on the hand the right 
hand rested, palm down on the vibration board, on a table (Figure 4). During the sensory 
threshold assessment on the foot the right foot was rested, sole down, on the vibration board on 
the floor (Figure 5). The vibration board was a ceramic board with a foam base designed to 
dampen any unwanted vibrations transmitted through the table or the floor. Skin surface 
temperature was measured prior to the thermal test on the hand and foot using an infrared 
thermometer (C-500 C, Linear Laboratories, CA). 
 
Units of stimulus intensity used were JND's (Just Noticeable Differences). Vibration, cooling and 
warming stimuli were increased and decreased using the 4, 2 and 1 stepping method devised by 
Dyck.
117
 This method was chosen for its accuracy and speed. Heat-pain was increased and 
decreased using the heat pain non-repeating ascending with null stimuli method.
118
 Using this 
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method it was possible to compare the heat-pain detection threshold (HP:0.5) and the 
intermediate heat-pain response (HP:5.0).
118
 
 
2.2.6 Procedure 
Testing was carried out in the Wellcome Trust Clinical Research Facility at the Queen Elizabeth 
Hospital, Birmingham, United Kingdom. The testing room was quiet, had sufficient light and air 
circulation and was at a comfortable temperature, free from drafts. Each participant attended a 
single 1 hour session. 
 
On arrival at the clinic, participants were introduced and briefed on the experiment before signing 
a consent form. Their height (m), weight (kg), waist (cm) and hips (cm) were then measured. 
Participants sat comfortably in a chair next to a table and any questions they had were answered. 
Participant‟s risk factors and family history were then obtained by means of a questionnaire. This 
included questions about ethnicity, smoking, drinking habits, salt intake, exercise and family 
history of heart disease, diabetes and hypertension. Three resting blood pressure measurements 
were then obtained from the right upper arm before commencing the sensory tests. 
 
During the session vibration, cooling, warming and heat-pain thresholds of the right hand and 
foot were determined using the CASE IV system (WR Medical Electronics Co., USA).  
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2.2.6.1 Quantitative Sensory Testing (QST) of Vibratory Perception 
Vibration sensation assesses myelinated Aβ fibre function. Vibratory perception was measured 
on the dorsal surface of the right index finger followed by the right big toe, in the midline 
between the nail bed and the most distal knuckle. Normative data has been obtained at these body 
sites in healthy individuals (aged 3-79 years).
119
  
 
2.2.6.1.1 Vibratory Testing in the Hand and Foot 
Participants placed their right hand/foot (plantar surface down) onto the vibration board. The 
vibration stimulator was placed on the participant‟s right index finger/big toe in the midline 
between the base of the nail and the most distal knuckle. The stimulator was adjusted so that its 
body was horizontal using a knob, checking the level bubble. Instructions for the vibration test 
were read out and any questions were answered. Instructions were read from a pre-prepared sheet 
to ensure that all participants were given identical information. The need for the participants to 
wear headphones for this test was explained (the headphones played noise to block out any 
external noises) and the headphones were placed on the participant. Participants were required to 
press „yes‟ or „no‟ on the response device as to whether they felt a stimulus during the display of 
the number „1‟ on the cue device. Practice tests were performed to estimate the threshold then the 
vibration test was performed. If two positive responses were given to null stimuli the test was 
repeated. 
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2.2.6.2 QST of Cooling, Warming and Heat-Pain Perception 
Cooling sensation assesses thinly myelinated Aδ fibre function and warming and heat-pain 
sensations assess unmyelinated C fibres. Thermal and heat-pain perception were measured on the 
dorsal surface of the participant‟s right foot followed by the right hand. 
 
2.2.6.2.1 Cooling, Warming and Heat-Pain Testing of the Right Foot 
Participants put a sock on into which a hole had been cut. The purpose of the sock was to insulate 
the foot. The temperature of the participant‟s foot was measured. The thermal stimulator was 
placed on the dorsal surface of the participant‟s right foot through the hole, ensuring the surface 
was flat against the skin and was in contact with the skin at all four corners. Instructions were 
read out for the cooling test and any questions were answered. Participants were required to 
respond „yes‟ or „no‟ on the response device as to whether they felt a stimulus during the display 
of the number „1‟ on the cue device. Practice tests were performed to estimate the threshold and 
the cooling test was performed. If two positive responses were given to null stimuli the test was 
repeated. 
 
Instructions for the warming test were read out and any questions were answered. Participants 
were required to respond „yes‟ or „no‟ on the response device as to whether they felt a stimulus 
during the display of the number „1‟ on the cue-device. Practice tests were performed to estimate 
the threshold and then the warming test was performed. If two positive responses were given to 
null stimuli the test was repeated. 
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Instructions for the heat-pain test were read out and any questions were answered. Participants 
were reassured that we would be testing them only at low discomfort and pain levels and were 
told that they should inform us if the stimuli got too high and they did not wish to continue. 
Participants were required to verbally rate any discomfort or pain felt during the display of the 
number „1‟ on the patient cue device on a scale from 0-10 (0=nothing or warm or hot, 1=lowest 
level of discomfort or pain, 10=most severe pain). These responses were typed into the laptop. As 
soon as participants rated the pain as 5 or above the test stopped. A pain rating of „1‟ 
corresponded to the heat-pain detection threshold (HP: 0.5) and a rating of 5 or above 
corresponded to the intermediate heat pain response (HP: 5.0). It was explained to the 
participants that there was no practice for this test. Then the heat-pain test was performed. If a 
positive result was given to null stimuli the test was repeated. 
 
2.2.6.2.2 Cooling, Warming and Heat-Pain Testing of the Right Hand 
The same thermal and heat pain tests were performed on the participant‟s right hand. 
The temperature of the participant‟s hand was measured. The thermal stimulator was positioned 
on the dorsal surface of the participant‟s right hand ensuring all four corners were in contact with 
the skin. Cooling, warming and heat-pain tests were performed as on the foot. 
 
In several instances the participants did not report notable pain or warming even at the highest 
stimulus intensity of the instrument. For these participants in whom the pain and/warming 
threshold was not measurable since it was above the upper range of stimulation, the highest 
available value of 25 JND (Just Noticeable Difference) was assigned. 
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Participants were free to withdraw at any time. All information obtained from the study was kept 
confidential and anonymous and participants were identified by subject number only. 
 
 
Figure 4. Measurement of Vibration Threshold in the Right Hand. The right hand rested on the 
vibration board and the vibration stimulator was placed on the index finger, in the midline 
between the base of the nail and the most distal knuckle. 
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Figure 5. Measurement of Thermal and Heat-Pain Thresholds in the Right Foot. Participants 
wore a sock with a hole in its dorsal surface. The thermal stimulator was strapped onto the dorsal 
surface of the foot, through the hole, so that all four corners of the stimulator were in contact with 
the skin. 
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2.2.7 Statistical Analysis  
Results were analysed using statistical software (PASW Statistics 18, SPSS Inc., Chicago). The 
two groups (hypertensive and normotensive) were compared using various statistical tests. First, 
an independent-samples T Test was used to determine differences in continuous variables 
between the hypertensive males and normotensive males, and between the hypertensive females 
and normotensive females. Second, Chi-square analysis was used to determine differences in 
categorical variables between the hypertensive and normotensive group. Third, the sensory 
thresholds of the hypertensive and normotensive group were compared using one-way analyses 
of variance (ANOVA). Fourth, the sensory thresholds of the hypertensive and normotensive 
group were compared using univariate analysis of covariance (ANCOVA), which allowed 
adjustment for the influence of potential confounders such as age, sex and BMI. This was 
necessary because age, sex and BMI are known to influence peripheral nerve 
dysfunction.
114;115;120;121
 Finally, Spearman‟s correlation coefficients were calculated for all 
sensory thresholds against mean systolic and diastolic blood pressure measurements. A 
significance level of .05 was adopted for all the above analyses.  
 
2.2.8 Power Calculations  
We assessed each individual‟s peripheral nerve function using a battery of sensory tests. In the 
initial analyses, for each outcome measure yielded by these tests, we compared the scores among 
the hypertensives and normotensive group. With alpha at 0.05 and a total sample size of 45, the 
study is powered at 0.80 to detect a group difference by ANCOVA corresponding to an effect 
size of f=0.43, which corresponds to a large effect size.
122
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2.3 Results and Brief Discussion 
2.3.1 Group Characteristics and Risk Factors of Each Blood Pressure Group  
Continuous variables of the hypertensive and normotensive males are presented in Table 5 and 
Figure 6. An independent-sample T Test confirmed that, compared to the normotensive males the 
hypertensive males exhibited significantly higher SBP, DBP, age, weight and BMI but the groups 
did not differ in terms of height or alcohol consumption (Table 5). 
 
Continuous variables of hypertensive and normotensive females are presented in Table 6 and 
Figure 7. An independent-sample T Test confirmed that, compared to the normotensive females 
the hypertensive females exhibited significantly higher SBP and DBP but the groups did not 
differ in terms of age, height, weight, BMI or alcohol consumption (Table 6). 
-55- 
Table 5. Unadjusted Mean [Standard Deviation (SD)], Blood Pressures, Age, Height, Weight, BMI and Alcohol Consumption of the 
Hypertensive and Normotensive Males as well as the Degrees of Freedom, t-Values and Statistical Significance Level of the Group 
Effects 
Variable  Mean (SD) 
Hypertensive 
Males 
n=12 
Mean (SD) 
Normotensive 
Males 
n=9 
F Sig. t 
 
df Sig.  
(2-tailed) 
Mean 
Difference 
Standard 
Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
SBP (mmHg) 
 
156.25 (16.64) 
 
122.89 (11.92) 
 
0.60 
 
 
0.45 
 
5.10 
 
19 
 
<0.001** 
 
33.36 
 
6.54 
 
19.67 
 
47.06 
DBP (mmHg) 98.83 (11.04) 73.78 (6.40) 2.81 0.11 6.06 19 <0.001** 25.06 4.13 16.40 33.71 
Age (years) 36.00 (7.70) 28 (4.18) 2.00 0.17 2.81 19 <0.05* 8.00 2.85 2.04 13.96 
Height (m) 1.81 (0.10) 1.79 (0.06) 2.75 0.11 0.57 19 0.57 0.02 0.04 -0.06 0.10 
Weight (kg) 99.80 (18.42) 73.24 (13.05) 0.85 0.37 3.68 19 <0.05* 26.56 7.22 11.44 41.67 
BMI (kg/m
2
) 30.58 (4.56) 22.89 (3.30) 1.25 0.28 4.28 19 <0.001** 7.69 1.80 3.93 11.46 
Alcohol 
(units/week) 
6.63 (7.00) 3.03 (4.84) 3.34 0.08 1.32 19 0.20 3.60 2.73 -2.11 9.30 
*= significant group difference at 0.05 level  **=significant group difference at 0.001 level 
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Table 6. Unadjusted Mean (SD), Blood Pressures, Age, Height, Weight, BMI and Alcohol Consumption of the Hypertensive and 
Normotensive Males as well as the Degrees of Freedom, t-Values and Statistical Significance Level of the Group Effects 
Variable  Mean (SD) 
Hypertensive 
Females 
n=8 
Mean (SD) 
Normotensive 
Females 
n=16 
F Sig. t 
 
df Sig.  
(2-tailed) 
Mean 
Difference 
Standard 
Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
SBP (mmHg) 
 
148.38 (8.45) 
 
113 (15.44) 
 
1.48 
 
0.24 
 
6.00 
 
22 
 
<0.001** 
 
35.38 
 
5.89 
 
23.15 
 
47.60 
DBP (mmHg) 96.50 (6.41) 71.81 (11.31) 2.22 0.15 5.69 22 <0.001** 24.69 4.34 15.69 33.68 
Age (years) 36.38 (10.62) 34.31 (10.35) 0.14 0.71 0.46 22 0.65 2.06 4.52 -7.31 11.44 
Height (m) 1.66 (0.06) 1.63 (0.06) 0.00 0.97 1.09 22 0.29 0.03 0.03 -0.03 0.08 
Weight (kg) 73.28 (18.52) 63.22 (12.11) 2.50 0.13 1.61 22 0.12 10.06 6.26 -2.93 23.04 
BMI (kg/m
2
) 26.75 (5.65) 23.88 (4.21) 1.18 0.29 1.41 22 0.17 2.88 2.04 -1.36 7.11 
Alcohol 
(units/week) 
3.75 (3.81) 2.58 (4.20) 0.30 0.59 0.66 22 0.51 1.17 1.77 -2.49 4.84 
*= significant group difference at 0.05 level  **=significant group difference at 0.001 level 
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Figure 6. Unadjusted Mean and Standard Deviation of all Continuous Variables of the 
Hypertensive Males and the Normotensive Males * Denotes a Significant Difference at the 0.05 
Level. 
* 
* 
* 
* 
* 
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Figure 7. Unadjusted Mean and Standard Deviation of all Continuous Variables of the 
Hypertensive Females and the Normotensive Females * Denotes a Significant Difference at the 
0.05 Level. 
 
Categorical variables are presented in Table 7. Chi-square analysis revealed that the hypertensive 
and normotensive group did not differ significantly in terms of sex, smoking status, exercise or 
salt intake. However, there was a significantly higher incidence of family history of hypertension 
in the hypertensive group. 
* 
* 
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Table 7. Number of Males and Females and Number and Percentage of Cardiovascular Risk 
Factors in the Hypertensive and Normotensive Group as well as the Degrees of Freedom, Chi-
square Values and Statistical Significance Levels of the Group Effects 
  n=20 
Hypertensives 
n=25 
Normotensives 
 
df 
 
χ2 
 
p 
  Number of 
participants 
% Number of 
participants 
%    
Sex Male 
Female 
12 
8 
 9 
16 
 1 2.57 0.11 
Family history of HT Yes 
No 
14 
5 
74 6 
18 
25 1 10.10 <0.001** 
Smoker/Ex-smoker Yes 
No 
8 
12 
40 4 
21 
16 1 3.27 0.07 
Exercise <5x30mins/week Yes 
No 
7 
8 
47 14 
10 
58 1 0.04 0.84 
Excess salt Yes 
No 
7 
13 
35 12 
13 
48 1 1.97 0.16 
Features consistent with the 
metabolic syndrome 
Yes 
No 
11 
6 
65 NK NK    
*= significant group difference at 0.05 level         **=significant group difference at 0.001 level        NK, Not Known 
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2.3.2 Analysis of Co-Variance and Spearman’s Correlation Coefficients on Sensory 
Threshold Data Obtained from CASE IV 
Because age, sex and BMI are known to influence peripheral nerve function and were different 
between blood pressure groups, these variables were adjusted for in the univariate analysis of co-
variance (ANCOVAs) that follow.
114;115;120;121
 
 
A series of one-way analysis of variance (ANOVAs) were performed on vibration, cooling, 
warming and heat-pain thresholds in the right hand and foot (Table 8). These analyses revealed a 
significant group difference for vibration threshold in the foot, cooling threshold in the hand, and 
vibration threshold in the hand. The hypertensive group exhibited higher vibration thresholds in 
the hand and foot than the normotensive group but lower cooling thresholds in the hand. 
 
A series of univariate analysis of co-variance (ANCOVAs), adjusted for age, sex and BMI were 
performed on vibration, cooling, warming and heat-pain thresholds in the right hand and foot 
(Table 9). These analyses revealed a significant group difference for vibration threshold in the 
foot. The hypertensive group exhibited higher vibration thresholds in the foot than the 
normotensive group. Unadjusted mean sensory thresholds of the hypertensive and normotensive 
group are presented in Figure 8. 
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Table 8. ANOVA. Unadjusted Mead (SD) Sensory Thresholds of the Hypertensive and 
Normotensive Group, as well as the Degrees of Freedom, F Values, Statistical Significance Level 
of the Group Effects and Associated Effect Size 
Variable Hypertensives Normotensives df F p η2 
Cooling 
Threshold Foot 
8.87 (4.23) 9.83 (3.92) 1 0.63 0.43 0.01 
Warming 
Threshold Foot 
14.72 (5.66) 14.70 (4.66) 1 0.00 0.99 0.00 
Vibration 
Threshold Foot 
16.50 (2.50) 13.91 (1.64) 1 17.55 <0.001** 0.29 
Heat-Pain 5.0 
Foot 
22.80 (2.21) 22.54 (2.67) 1 0.12 0.73 0.00 
Heat-Pain 0.5 
Foot 
19.72 (2.02) 18.71 (2.62) 1 2.01 0.16 0.05 
Cooling 
Threshold Hand 
8.02 (2.25) 9.55 (2.54) 1 4.50 0.04* 0.10 
Warming 
Threshold Hand 
9.85 (2.53) 11.68 (3.32) 1 4.16 0.05 0.09 
Vibration 
Threshold Hand 
11.15 (2.13) 9.77 (1.32) 1 7.10 0.01* 0.14 
Heat-Pain 5.0 
Hand 
22.45 (2.08) 21.85 (2.36) 1 0.79 0.38 0.02 
Heat-Pain 0.5 
Hand 
19.10 (2.14) 18.08 (2.58) 1 2.03 0.16 0.05 
*= significant group difference at 0.05 level  **=significant group difference at 0.001 level 
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Table 9. ANCOVA. Unadjusted Mean (SD) Sensory Thresholds of the Hypertensive and 
Normotensive Group, as well as the Degrees of Freedom, F Values, Statistical Significance Level 
of the Group Effects (Adjusted for Age, Sex and BMI) and Associated Effect Size 
Variable Hypertensives Normotensives df F p η2 
Cooling 
Threshold Foot 
8.87 (4.23) 9.83 (3.92) 1 0.36 0.56 0.01 
Warming 
Threshold Foot 
14.72 (5.66) 14.70 (4.66) 1 1.25 0.27 0.03 
Vibration 
Threshold Foot 
16.51 (2.50) 13.91 (1.64) 1 8.98 0.01* 0.19 
Heat-Pain 5.0 
Foot 
22.80 (2.21) 22.54 (2.67) 1 0.04 0.84 0.00 
Heat-Pain 0.5 
Foot 
19.72 (2.02) 18.71 (2.62) 1 0.49 0.49 0.01 
Cooling 
Threshold Hand 
8.02 (2.25) 9.55 (2.54) 1 1.51 0.23 0.04 
Warming 
Threshold Hand 
9.85 (2.53) 11.68 (3.32) 1 3.02 0.09 0.07 
Vibration 
Threshold Hand 
11.15 (2.13) 9.77 (1.32) 1 4.11 0.05 0.10 
Heat-Pain 5.0 
Hand 
22.45 (2.08) 21.85 (2.36) 1 0.20 0.66 0.01 
Heat-Pain 0.5 
Hand 
19.10 (2.14) 18.08 (2.58) 1 1.173 0.29 0.03 
*= significant group difference at 0.05 level  **=significant group difference at 0.01 level 
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Figure 8. Unadjusted Mean and Standard Deviation of all Sensory Thresholds of the 
Hypertensive and Normotensive Groups * Denotes a Significant Group Difference at the 0.05 
Level after Adjusting for Age, Sex and BMI 
 
Spearman‟s correlation coefficients were calculated for all sensory thresholds against mean 
systolic and diastolic blood pressure measurements (Table 10). These analyses revealed a 
significant positive correlation between systolic and diastolic blood pressure and vibration 
threshold in the foot (Figure 9). Interestingly, there was a significant negative correlation between 
systolic and diastolic BP and cooling in the hand (Figure 10), and between systolic and diastolic 
blood pressure and warming in the hand (Figure 11).  
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Table 10. Spearman‟s Correlation Coefficients for all Sensory Thresholds against Mean Systolic 
and Diastolic Blood Pressure Measurements 
Threshold Systolic BP Diastolic BP 
Cooling Threshold 
Foot 
Correlation 
Coefficient 
Sig. (2-tailed) 
-0.16 
 
0.30 
Correlation 
Coefficient 
Sig. (2-tailed) 
-0.20 
 
0.19 
Warming 
Threshold Foot 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.03 
 
0.84 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.06 
 
0.68 
Vibration 
Threshold Foot 
Correlation 
Coefficient 
Sig.(2-tailed) 
0.47 
 
<0.001** 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.38 
 
0.01* 
Heat-Pain 5.0 Foot Correlation 
Coefficient 
Sig. (2-tailed) 
0.04 
 
0.82 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.02 
 
0.91 
Heat-Pain 0.5 Foot Correlation 
Coefficient 
Sig. (2-tailed) 
0.23 
 
0.14 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.24 
 
0.11 
Cooling Threshold 
Hand 
Correlation 
Coefficient 
Sig. (2-tailed) 
-0.42 
 
<0.001* 
Correlation 
Coefficient 
Sig. (2-tailed) 
-0.37 
 
0.01* 
Warming 
Threshold Hand 
Correlation 
Coefficient 
Sig. (2-tailed) 
-0.39 
 
0.01* 
Correlation 
Coefficient 
Sig. (2-tailed) 
-0.38 
 
0.01** 
Vibration 
Threshold Hand 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.19 
 
0.20 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.25 
 
0.10 
Heat-Pain 5.0 Hand Correlation 
Coefficient 
Sig. (2-tailed) 
0.07 
 
0.66 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.09 
 
0.55 
Heat-Pain 0.5 Hand Correlation 
Coefficient 
Sig. (2-tailed) 
0.09 
 
0.56 
Correlation 
Coefficient 
Sig. (2-tailed) 
0.11 
 
0.49 
*= significant group difference at 0.05 level  **=significant group difference at 0.001 level 
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Figure 9. Scatter Graph Showing Vibration Threshold in the Foot (x) against Systolic and 
Diastolic Blood Pressure (y) 
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Figure 10. Scatter Graph Showing Cooling Threshold in the Hand (x) against Systolic and 
Diastolic Blood Pressure (y) 
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Figure 11. Scatter Graph Showing Warming Threshold in the Hand (x) against Systolic and 
Diastolic Blood Pressure (y) 
-68- 
2.3.3 Brief Discussion 
To our knowledge, the current study was the first to use quantitative sensory testing (QST) to 
investigate different sensory thresholds in order to assess different nerve fibres (small as well as 
large) in a group of newly diagnosed unmedicated essential hypertensives as well as in a group of 
normotensive controls to investigate whether hypertensives have subclinical peripheral 
neuropathy. In previous studies cutaneous detection thresholds, current perception thresholds, 
sensory nerve conduction velocities and sensory action potentials were used to measure nerve 
function in general.
65;66;68;70
 Earlier studies investigating peripheral nerve function in 
hypertensives did not measure specific senses, and measured pain by other means but not by the 
heat-pain method used in this study.
65-70;83;84
 
 
The hypertensive males exhibited more risk factors for hypertension and cardiovascular disease 
than the normotensive males including significantly higher SBP, DBP, weight and BMI. The 
hypertensive females had significantly higher SBP and DBP than the normotensive females. The 
hypertensive group had significantly higher incidence of family history of hypertension than the 
normotensive group. It is important to note that the significantly higher weight and BMI of the 
hypertensive males may be confounding variables in this study. In addition, 65% of the 
hypertensive group had features consistent with the metabolic syndrome, which may be 
contributing to peripheral neuropathy rather than hypertension alone. Other possible confounders 
such as age, sex and alcohol consumption, however, were not significantly different between the 
hypertensive and normotensive group. 
 
* 
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The major findings of this study were as follows. 1) The hypertensive group had significantly 
higher vibration thresholds in the foot than the normotensive group, even after accounting for 
age, sex and BMI. 2) There was a significant positive correlation between SBP and DBP with 
vibration threshold in the foot. 3) There was a significant negative correlation between SBP and 
DBP with both cooling and warming thresholds in the hand. 
 
The findings of increased vibration thresholds in the foot in the hypertensive group and of a 
positive correlation between SBP and DBP with vibration threshold support our hypothesis and 
some previous evidence of peripheral neuropathy in hypertension. 
 
It is worth mentioning that vibration threshold in the hand was significantly higher in the 
hypertensive group before age, sex and BMI were accounted for. However, after accounting for 
these confounding variables the significance diminished, indicating that age, sex and/or BMI 
were contributing to the significant difference between groups rather than blood pressure alone. 
This supports evidence that age, sex and BMI influence peripheral nerve function.
114;115;120;121
 
Similarly, the significant group difference for cooling threshold in the hand diminished once age, 
sex and BMI were accounted for. With this in mind, it is possible that the significant negative 
correlation between SBP and DBP with cooling threshold in the hand may also disappear once 
these confounding factors are accounted for. This may also be the case for the significant 
negative correlation for warming in the hand. However, hierarchical linear regression analyses 
would have to be performed to investigate this.  
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Notably, all warming thresholds in the foot and heat-pain thresholds were higher in the 
hypertensive group even after adjusting for age, sex and BMI but not to a significant degree. 
However, these may become more significant with a larger sample size. 
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CHAPTER 3: STUDY TWO - RETROSPECTIVE DATABASE 
ANALYSIS OF CARDIOVASCULAR RISK IN CONFIRMED AND 
BORDERLINE HYPERTENSIVE PATIENTS 
3.1 Introduction 
Chapter two demonstrated some evidence of subclinical peripheral neuropathy, which may 
suggest damage to peripheral nerve vasculature in unmedicated hypertensives. The sample size 
was not large enough to determine whether these changes were happening in all grades of 
hypertension. However, vibration threshold was particularly affected and this appeared to be 
correlated with the level of blood pressure. This chapter will use information from our 
Hypertension Database to compare cardiovascular risk factors including features consistent with 
the metabolic syndrome and ambulatory arterial stiffness index (AASI) in a much larger group of 
confirmed hypertensives (n=83) and borderline hypertensives (n=154). 
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3.1.1 The Hypertension Database 
The Hypertension Database (Microsoft Access 2002) contains extensive information on all new 
referrals to the Hypertension Clinic since May 2006. The database is updated every week at clinic 
from the patient‟s medical notes. Recorded information includes: hospital ID, initials, gender, 
date of birth, ethnicity, family history of hypertension, gestational hypertension, co-morbidities, 
current medications, risk factors (smoking, salt, exercise and alcohol consumption), reason for 
referral, clinic variables including waist, height, weight, BMI, mean clinic blood pressures, 
urinalysis results, fasting blood results including sugar, electrolytes, renal function, lipid profiles 
etc., electrocardiogram findings, ABPM findings including mean daytime and mean night time 
blood pressures, dipper status (i.e. whether or not the blood pressure is lower when the patient is 
asleep), clinical diagnosis based on ABPM results, record of any  secondary investigations 
undertaken e.g. renal ultrasound, renin:aldosterone ratio etc., any changes to medications 
recommended to the general practitioner and further management plans e.g. lifestyle advice, 
repeat ABPM, discharge.  
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3.2 Methods  
3.2.1 Establishment of Blood Pressure Status 
Patients were categorised as having either confirmed or borderline hypertension depending on 
their mean clinic blood pressure readings and their mean daytime ABPM reading, which were 
available from the Hypertension Database. Account was taken of the 10/5 mmHg adjustment of 
ambulatory readings recommended by the BHS.
3
 However, it is worth mentioning that the use of 
this adjustment is controversial and is not uniform across blood pressure levels. Confirmed 
hypertension was defined as sustained systolic blood pressure at referral of ≥160 mmHg or a 
diastolic blood pressure of ≥100mmHg, which was confirmed at clinic and on ABPM. 
Borderline hypertension was defined as sustained systolic blood pressure at referral of 140-159 
mmHg or a diastolic blood pressure of 90-99 mmHg, which was confirmed at clinic and on 
ABPM.   
 
3.2.2 Exclusion Criteria 
Patients were excluded if they were taking any prescription medications, if there was evidence of 
secondary hypertension (renal or adrenal causes) or if they had any disease/disorder other than 
hypertension. 
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3.2.3 Database Analysis 
1. Patient demographics (age, height, weight and BMI) and blood pressures (clinic and 
ABPM) were compared between the confirmed hypertensive group and the borderline 
hypertensive group. 
2. Cardiovascular and/or hypertension risk factor profiles (sex, family history of 
hypertension, smoking, salt intake, exercise, alcohol intake and electrolytes) of the two 
groups were then compared. These analyses included a calculation of the 10 year 
coronary and CVD risk score in both groups calculated using the Framingham equation, 
which takes into account age, sex, SBP, DBP, cholesterol, HDL cholesterol, smoking, 
diabetes, and ECG-LVH.
15
 
3. Ambulatory Arterial Stiffness Index (AASI) for each individual was calculated from their 
ABPM readings. The mean AASI of each group was compared. AASI was defined as 1 
minus the regression slope of diastolic over systolic blood pressure readings obtained 
from 24-hour ABPM recordings. AASI gives a measure of arterial stiffness and thus 
cardiovascular risk.
55
 The closer the AASI to 1, the stiffer the arteries.
61
 
4. Body Mass Index (BMI), triglycerides, HDL cholesterol, blood pressure and fasting 
plasma glucose were used to determine the number of patients with features consistent 
with the metabolic syndrome.
62
 Please note that waist measurements were not available 
for all patients so BMI was used to calculate metabolic syndrome. According to Alberti et 
al., 2005, „if body-mass index is over 30 kg/m2, central obesity can be assumed and waist 
circumference does not need to be measured.‟62 
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3.2.4 Statistical Analysis 
Results were analysed using statistical software (PASW Statistics 18, SPSS Inc., Chicago). The 
two groups (confirmed hypertensive and borderline hypertensive) were compared using various 
statistical tests. First, an independent-samples T Test was used to determine differences in 
continuous variables between the confirmed hypertensive and borderline hypertensive group. 
Second, Chi-square analysis was used to determine differences in categorical variables between 
the confirmed hypertensive and borderline hypertensive group. Finally, the continuous variables 
were compared using univariate analysis of covariance (ANCOVA), which allowed adjustment 
for the influence of potential confounders such as age and sex. This was necessary because age 
and sex are known cardiovascular risk factors. A significance level of 0.05 was adopted for all 
the above analyses. 
 
This was a retrospective analysis of a large database. It was not a prospective study so did not 
require a power calculation. The maximum number of patients that fulfilled the study criteria 
were pulled from the database for analysis.  
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3.3 Results and Brief Discussion 
3.3.1 Group Characteristics and Cardiovascular Risk Factors of Each Blood Pressure 
Group 
Group blood pressures and participant characteristics are presented in Table 11. An independent-
sample T Test was performed on the patient demographics and blood pressures (Table 11). These 
analyses confirmed that, compared to the borderline group the confirmed hypertensive group 
exhibited significantly higher mean clinic SBP in the right arm, mean clinic DBP in the right 
arm, mean clinic SBP in the left arm, mean clinic DBP in the left arm, ABPM daytime SBP, 
ABPM daytime DBP, ABPM nighttime SBP, ABPM nighttime DBP and age. However, the 
groups did not differ in terms of height, weight or BMI (Table 11). 
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Table 11. Independent-Samples T Test. Unadjusted Mean (SD), Blood Pressures and Demographics of the Confirmed Hypertensive 
and Borderline Hypertensive Group as well as the Degrees of Freedom, t-Values and Statistical Significance Level of the Group 
Effects 
Variable Mean (SD) 
Confirmed 
HT’s 
Mean (SD) 
Borderline 
HT’s 
F Sig. t 
 
df Sig. 
(2-tailed) 
Mean 
Difference 
Standard 
Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Mean Clinic SBP right 
arm (mmHg) 
170.31 (19.06) 153.39 (13.90) 9.45 <0.001** -7.15 132.97 <0.001** -16.92 2.37 -21.60 -12.24 
Mean Clinic DBP right 
arm (mmHg) 
96.83 (13.20) 90.89 (9.81) 5.58 0.02* -3.61 135.08 <0.001** -5.95 1.65 -9.21 -2.69 
Mean Clinic SBP left arm 
(mmHg) 
170.08 (19.57) 151.89 (15.56) 4.83 0.03* -7.30 139.72 <0.001** -18.19 2.49 -23.12 -13.26 
Mean Clinic DBP left 
arm (mmHg) 
95.66 (11.22) 89.81 (10.33) 0.57 0.45 -4.02 232 <0.001** -5.86 1.46 -8.72 -2.99 
ABPM daytime SBP 
(mmHg) 
154.80 (10.23) 138.61 (6.27) 19.91 <0.001** -13.20 118.02 <0.001** -16.18 1.23 -18.61 -13.76 
ABPM daytime DBP 
(mmHg) 
95.29 (9.99) 88.44 (6.48) 17.51 <0.001** -5.66 122.25 <0.001** -6.84 1.21 -9.24 -4.45 
ABPM nighttime SBP 
(mmHg) 
136.46 (16.31) 121.57 (9.60) 6.62 0.01* -7.66 115.69 <0.001** -14.90 1.94 -18.75 -11.04 
ABPM nighttime DBP 
(mmHg) 
80.48 (12.53) 73.07 (8.69) 11.20 <0.001** -4.82 128.31 <0.001** -7.41 1.54 -10.46 -4.37 
Age (years) 
 
51.84 (15.79) 40.79 (12.53) 4.76 0.03* -5.56 143.02 <0.001** -11.05 1.99 -14.98 -7.12 
Height (m) 
 
1.69 (.11) 1.70 (.10) 0.06 0.81 0.43 232 0.67 0.006 0.01 -0.02 0.03 
Weight (kg) 
 
81.32 (17.47) 81.84 (15.22) 0.35 0.56 0.22 235 0.83 0.51 2.34 -4.11 5.13 
BMI (kg/m2) 28.42 (5.22) 28.45 (5.49) 1.45 0.23 0.04 232 0.97 0.03 0.74 -1.42 1.48 
*=significant group difference at 0.05 level  **=significant difference at 0.001 level 
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ANCOVA demonstrated that all blood pressures (mean clinic SBP in the right arm, mean clinic 
DBP in the right arm, mean clinic SBP in the left arm, mean clinic DBP in the left arm, ABPM 
daytime SBP, ABPM daytime DBP, ABPM nighttime SBP and ABPM nighttime DBP) remained 
significantly higher in the confirmed hypertensive group even after accounting for age and sex, F 
(1) = 36.39, p = <0.001,  F (1) = 18.24, p = <0.001, F (1) = 37.77, p = <0.001, F (1) = 17.82, p = 
<0.001, F (1) = 180.49, p = <0.001, F (1) = 52.74, p = <0.001, F (1) = 64.90, p = <0.001  and F 
(1) = 30.04, p = <0.001 respectively. 
 
Similarly, height, weight and BMI remained insignificantly different between groups once age 
and sex were accounted for, F (1) = 0.95, p = 0.33, F (1) = 0.01, p = 0.93 and F (1) = 0.04, p = 
0.84 respectively. 
 
Patient cardiovascular risk factors are presented in Table 12. The confirmed hypertensive group 
had more male patients (46% vs 42%, p<0.03). Most patients had a positive family history of 
hypertension (65% of the hypertensive group vs 69% of the borderline group), about a quarter of 
both groups were smokers/ex-smokers (24% vs 26%), over a third had self reported excess salt in 
their diet (39% vs 44%), over 50% in each group did less than the recommended amount of 
exercise each week and over 15% of each group drank in excess of the recommended weekly 
allowance of alcohol. Finally, over a quarter of patients in each group had a profile compatible 
with the metabolic syndrome. There were statistically significant differences between the two 
groups: the borderline group was more likely to have a family history of hypertension, smoke, 
take excess salt, drink over the recommended limit and were less likely to have features 
consistent with the metabolic syndrome. It was not clear why the two groups had different risk 
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factors. Some of the differences might suggest that the borderline patients were less aware of 
modifiable risks and lifestyle interventions, possibly because their diagnosis was more recent. 
Clinically, however, both groups presented with a similar profile of modifiable and non-
modifiable risk factors. 
 
Table 12. Number of Males and Females and Number and Percentage of Cardiovascular Risk 
Factors in the Confirmed and Borderline Hypertensive Groups as well as Degrees of Freedom, 
Chi-Square and Statistical Significance Levels of the Group Effects 
  n=83 
Confirmed 
Hypertensives 
n=154 
Borderline 
Hypertensives 
 
df 
 
χ2 
 
p 
  Number of 
particpants 
% Number of 
particpants 
%    
Sex Male 
Female 
38 
45 
44 
54 
65 
89 
42 
58 
1 4.56 0.03* 
Family History of HT Yes 
No 
55 
30 
65 106 
47 
69 1 29.65 <0.001** 
Smoker/Ex smoker<5 years Yes 
No 
20 
64 
24 40 
114 
26 1 294.13 <0.001** 
Excess Salt Yes 
No 
33 
51 
39 67 
87 
44 1 6.07 0.01* 
Exercise <5x30mins/week Yes 
No 
47 
37 
56 87 
67 
57 1 3.78 0.05 
Drink > recommended 
weekly allowance of alcohol 
Yes 
No 
14 
69 
17 29 
125 
19 1 96.21 <0.001** 
Features consistent with the 
metabolic syndrome 
Yes 
No 
25 
60 
29 38 
116 
25 1 53.43 <0.001** 
*=significant group difference at 0.05 level  **=significant difference at 0.001 level 
 
Patient biochemical values are presented in Table 13. An independent-sample T Test was 
performed on electrolyte values (Appendix A). These analyses confirmed that, compared to the 
borderline group the confirmed hypertensive group exhibited significantly higher urea and blood 
glucose. These differences were not clinically significant.  
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Table 13. Unadjusted Mean (SD), Biochemical Values of the Confirmed Hypertensive and 
Borderline Hypertensive Group as well as Degrees of Freedom, t Values and Statistical 
Significance Levels of the Groups Effects 
Electrolyte Confirmed 
Hypertensives 
Borderline 
Hypertensives 
df t p 
Sodium 141.24 (2.53) 140.40 (5.38) 231 -1.33 0.18 
Potassium 4.24 (0.35) 4.20 (0.34) 231 -0.99 0.32 
Urea 5.25 (1.23) 4.70 (0.96) 140.84 -3.51 <0.001** 
Creatinine 94.13 (13.63) 93.15 (15.13) 231 -0.49 0.63 
Total Cholesterol 5.19 (1.06) 5.20 (1.00) 234 0.11 0.91 
HDL Cholesterol 1.55 (0.51) 1.53 (0.45) 224 -0.34 0.73 
Triglycerides 1.69 (0.96) 1.52 (1.13) 231 -1.15 0.25 
GGT 34.78 (26.89) 37.67 (41.01) 228 0.58 0.57 
Calcium 2.31 (0.10) 2.32 (0.10) 229 0.07 0.95 
Glucose 5.44 (1.28) 5.07 (0.89) 126.16 -2.35 0.02* 
Urate 322.68 (81.54) 324.80 (92.79) 227 0.17 0.86 
*=significant group difference at 0.05 level  **=significant difference at 0.001 level 
 
ANCOVA demonstrated that urea remained significantly higher in the confirmed hypertensive 
group even after accounting for age and sex, F (1) = 4.46, p = 0.04 but this is of no clinical 
significance. However, the small difference in blood glucose was no longer significantly different 
between groups once age and sex were accounted for, F (1) = 1.88, p = 0.17. Interestingly, once 
age and sex were accounted for a group difference became apparent for total cholesterol, F (1) = 
4.37, p = 0.04, with total cholesterol being significantly higher in the confirmed hypertensive 
group. However, this difference was not clinically significant. 
 
Group AASI, 10 year coronary risk and 10 year CVD risk are presented in Table 14. An 
independent-sample T Test was performed on AASI, 10 year coronary risk and 10 year CVD risk 
(Appendix B). These analyses confirmed that, compared to the borderline group the confirmed 
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hypertensive group exhibited significantly higher AASI, significantly higher 10 year coronary 
risk, and significantly higher 10 year CVD risk.  
 
Table 14. Unadjusted Mean (SD), AASI, 10 Year Coronary Risk and 10 Year CVD Risk for the 
Confirmed Hypertensive and Borderline Hypertensive Group as well as Degrees of Freedom, t 
Values and Statistical Significance Level of the Group Effects 
 Confirmed 
Hypertensives 
Borderline 
Hypertensives 
df t p 
AASI 0.39 (0.16) 0.31 (0.16) 214 -3.85 <0.001** 
10 Year Coronary Risk 9.35 (8.14) 5.4 (6.21) 222 -4.04 <0.001** 
10 Year CVD Risk 17.8 (13.15) 9.38 (10.19) 134.91 -5.01 <0.001** 
*=significant group difference at 0.05 level  **=significant difference at 0.001 level 
 
ANCOVA demonstrated that the group difference for AASI remained significant even after 
accounting for age and sex, F (1) = 5.41, p = 0.02. However, 10 year coronary and 
Cardiovascular risk were no longer significantly different between groups once age and sex were 
accounted for, F (1) = 0.09, p = 0.76 and F (1) = 1.07,  p = 0.30 respectively. 
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3.3.2 Brief Discussion 
The confirmed hypertensives were significantly older and were more likely to have features 
consistent with the metabolic syndrome and stiffer arteries (as measured by AASI) than the 
borderline hypertensives. However, the borderline hypertensives had similar height, weight, BMI, 
amount of exercise, biochemical profile and 10 year coronary and CVD risk (once age and sex 
were accounted for) as the confirmed hypertensives. Both groups had a clinically similar  pattern 
of smoking, excess salt and higher than recommended amounts of alcohol and had a positive 
family history of hypertension in over 60% of cases. It is therefore apparent that all of these 
patients, including the borderline group, require intensive lifestyle advice at the very least. 
 
Metabolic syndrome and arterial stiffness are less standard cardiovascular risk factors but are 
important to take into consideration when assessing cardiovascular risk since individuals with 
metabolic syndrome are 1.69 times more likely to develop CVD than those without, and arterial 
stiffness is important for assessing cardiovascular risk as well as for predicting cardiovascular 
outcomes.
54;64
 One quarter of the borderline group had features consistent with the metabolic 
syndrome, which again suggests that these individuals should have aggressive lifestyle 
intervention. Although the AASI was significantly higher in the confirmed hypertensive group 
the values were still within the normal range possibly because the mean age in this group was 
fairly young. 
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CHAPTER 4: OVERALL DISCUSSION AND CONCLUSIONS 
4.1 Overall Discussion 
4.1.1 Summary of Main Findings 
Study One examined vibratory, cooling, warming and heat-pain thresholds in the right hand and 
foot of a group of newly diagnosed unmedicated essential hypertensives (BP ≥140/90 mmHg) as 
well as a group of normotensive controls, who were free from pre-existing peripheral neuropathy 
and associated symptoms. Study Two compared cardiovascular risk factors in a larger group of 
confirmed and borderline hypertensive patients selected from our Hypertension Database. 
 
The major findings from Study One were as follows. 1) The hypertensive group had significantly 
higher vibration thresholds in the foot than the normotensive group, even after accounting for 
age, sex and BMI. 2) There was a significant positive correlation between SBP and DBP with 
vibration threshold in the foot. 3) There was a significant negative correlation between systolic 
and diastolic blood pressure with both cooling and warming thresholds in the hand. 
 
The major finding from Study Two was that the borderline hypertensives had similar modifiable 
cardiovascular risk factors as the confirmed hypertensives, suggesting that lifestyle intervention 
is appropriate for reducing blood pressure and improving health in all grades of hypertension.  
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4.1.2 Detailed Discussion of Main Findings 
4.1.2.1 Study One 
Vibration threshold in the foot was significantly higher in the hypertensive group when compared 
to the normotensive group even after accounting for age, sex and BMI and there was a significant 
positive correlation between both systolic and diastolic BP and vibration threshold in the foot, 
supporting some existing evidence for peripheral neuropathy in hypertension.
65-70
 
 
Conversely, there was a significant negative correlation between systolic and diastolic BP and 
both cooling and warming thresholds in the hand. These unexpected contradictory findings 
oppose our hypothesis and some previous research but support other counter evidence suggesting 
that hypertension is in fact protective against peripheral neuropathy.
123;124
 The reasons for a 
possible negative association between hypertension and peripheral neuropathy remain 
unexplained.
123
 These significant negative correlations should be interpreted with some caution 
since we cannot exclude the possibility that confounding variables such as age, sex and BMI may 
be playing a part. It may be that when age, sex and BMI are accounted for using hierarchical 
linear regression analysis that the significance diminishes.  
 
The findings of significantly higher vibration thresholds in the foot of the hypertensive group and 
a significant positive correlation between both systolic and diastolic BP and vibration threshold in 
the foot supports some existing evidence for peripheral neuropathy in hypertension using a novel 
form of stimulation (QST). These findings suggests that peripheral nerve fibres, specifically large 
-85- 
myelinated A fibres that conduct vibration sensation, may be preferentially affected in 
hypertensives, particularly in their feet.  
 
Myelin degeneration might explain why vibration sensation (myelinated A fibres) rather than 
cooling (thinly myelinated Aδ fibres), warming or heat-pain (unmyelinated C fibres) sensations 
were preferentially affected. However, nerve conduction studies and/or nerve biopsies would 
have to be performed to confirm this. Still, if found to be true, this would support findings of 
Viskoper et al., 1971 who found a reduction in motor nerve conduction velocities in the upper 
extremities in hypertensives compared to normotensives as well as an inverse relationship 
between nerve conduction velocity and DBP.
112
 This theory is also supported, albeit indirectly, 
by the finding that in patients with vasculitic neuropathy, myelinated fibres are more vulnerable 
to ischaemia than unmyelinated fibres and large myelinated axons are affected before smaller 
ones.
125
 In contrast, Edwards et al., 2008 found that although cutaneous sensory thresholds were 
~30% higher and sensory action potentials were ~20% lower in hypertensives than 
normotensives, sensory nerve conduction velocity did not differ between groups suggesting that 
hypertension may cause axonal rather than demyelinating neuropathy.
70
 Also in contrast, in most 
neuropathies, including the most common type of diabetic neuropathy [Distal Symmetrical 
Sensory Polyneuropathy (DSSP)], it is the small nerve fibres (myelinated and unmyelinated) that 
detect temperature that are affected first followed by the large nerve fibres (myelinated) that 
detect vibration.
126;127
 Having said this, DSSP can be categorised into sub-types: small-fibre type, 
large-fibre type and mixed. The mixed sub-type is the most common but the small-fibre and 
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large-fibre types can occur independently. Large-fibre DSSP was often seen in the past when 
there was no treatment for diabetes, but is less common today.
127
  
 
The mechanisms underlying a possible hypertension-related axonal or demyelinating neuropathy 
are not known.
65-70;107
 Evidence suggests that the pathological process may be similar to that in 
diabetic neuropathy, whereby metabolic and vascular disturbances lead to structural and 
functional changes in blood vessels supplying peripheral nerves, resulting in ischaemia and 
hypoxia, which induces oxidative stress and injury to peripheral nerves possibly via an increase 
in production of reactive oxygen species (ROS).
87-91;101-103
  
 
Reactive oxygen species can damage the lipids, proteins, nucleic acids and mitochondria of cells, 
potentially causing cell death.
128
 Oligodendrocytes (brain cells that produce myelin) are more 
sensitive to oxidative stress in vitro than astrocytes and microglia, possibly due to their reduced 
glutathione (antioxidant) content, their higher iron content and their higher dependency on 
oxidative phosphorylation.
128
 Oxidative stress might therefore result in vivo in selective 
oligodendrocyte death and consequent demyelination. The ROS may also damage the myelin 
sheath, promoting its attack by macrophages.
128
 Schwann cells are the peripheral nervous system 
equivalent of oligodendrocytes, thus it seems reasonable to assume that Schwann cells may be 
similarly affected when under oxidative stress i.e. in preference to other nerve cells. In fact, Iida 
et al., 2004 found that Schwann cells are a specific target of oxidative injury and that there is 
some susceptibility of Schwann cells to even mild degrees of ischaemia.
129
 Furthermore, 
ischaemia can affect Schwann cells when not intense enough to cause axonal degeneration and 
chronic ischaemia is known to induce demyelination in addition to axonal loss.
130-133
 This would 
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perhaps go some way to explaining why loss of vibration sensation (myelinated A fibres) 
preceded loss of warming and heat-pain (small unmyelinated C-fibres) in the present study. 
However, at this stage this theory is somewhat fabricated and is based on rather scanty evidence. 
If the findings of the present study were replicated and causality was proven, laboratory studies 
would then be necessary in order to investigate the pathological mechanisms involved. 
 
The group difference for vibration threshold was significant in the foot (p =0.01) but not quite in 
the hand (p =0.05). This may be due to the fact that the hands are generally more sensitive than 
the feet because of their larger distribution on the homunculus. Consequently, the hands may be 
more effective than the feet at discriminating between vibration and non-vibration stimuli leading 
to a less significant difference between groups. Another, more simplistic explanation is that 
circulation is often better in the hands than the feet. Therefore, if poor blood supply to peripheral 
nerves does indeed contribute towards peripheral neuropathy, then the feet would be more 
noticeably affected. In addition, peripheral neuropathy usually occurs in a length dependent 
fashion i.e. the longest nerves (to the feet) are affected first.
126
 In fact, vibration threshold 
increases with age and is often first lost in the feet.
134
 
 
Only vibration threshold in the foot demonstrated a significant group difference once age, sex and 
BMI were accounted for. However, it is useful to note the trend between groups of all other 
sensory thresholds, despite them not reaching significance. Vibration threshold in the hand, 
warming threshold in the foot, heat-pain 5.0 in the hand and foot and heat-pain 0.5 in the hand 
and foot were higher in the hypertensive group after accounting for age, sex and BMI. 
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Conversely, cooling threshold in the hand and foot and warming threshold in the foot were lower 
in the hypertensive group after accounting for age, sex and BMI. 
 
Heat-pain and warming are both conducted by the same nerve fibres (unmyelinated C-fibres). 
Therefore, one might expect warming thresholds to also be higher in the hypertensive group. 
However, this was only true for warming threshold in the foot. These discrepancies between 
sensory thresholds introduce the prospect that hypertension may affect different peripheral nerve 
fibres differently; a possibility that warrants further investigation but that could be particularly 
true for heat-pain since there is evidence that hypertension-associated hypoalgesia may be caused 
by a central rather than peripheral mechanism, which may explain the inverse group difference 
for heat-pain and warming hand. However, in the present study it is more than likely that these 
discrepancies are due to the small sample size and that with a larger sample the results may have 
been more consistent and significant. In such a small sample the opposing results for cooling 
threshold in the hand and foot and warming threshold in the hand might reflect the large variation 
in heat sensitivity among individuals, which QST is not very effective at accounting for.
116
 
Similarly, the insignificant group difference for heat-pain thresholds might reflect the subjectivity 
of the heat-pain methodology and the large variation in pain thresholds among individuals. 
Hence, QST may not be the best methodology for detecting group differences in thermal and 
heat-pain thresholds. 
 
The findings of this small preliminary study indicate that newly diagnosed unmedicated essential 
hypertensives may have subclinical peripheral neuropathy in the form of reduced sensibility to 
vibration in their feet. However, this finding was not consistent across other sensory modalities or 
-89- 
in the upper limb. Due to the small sample and many other limitations of this study further 
studies with much larger sample sizes are needed in order to prove causality across all grades of 
hypertension and to look into the pathogenesis. 
 
4.2.1.2 Study Two 
Findings from the retrospective database analysis of cardiovascular risk demonstrated that 
unmedicated borderline hypertensives with no other medical conditions had similar 
cardiovascular risk factors and profiles as their confirmed hypertensive counterparts, suggesting 
that borderline hypertensives necessitate lifestyle advice at the very least. Most patients had a 
positive family history of hypertension (65% of the hypertensive group vs 69% of the borderline 
group), about a quarter of both groups were smokers/ex-smokers (24% vs 26%), over a third had 
self reported excess salt in their diet (39% vs 44%), over 50% in each group did less than the 
recommended amount of exercise each week and over 15% of each group drank in excess of the 
recommended weekly allowance of alcohol. Finally, over a quarter of patients in each group had 
a profile compatible with the metabolic syndrome, which would improve with lifestyle 
intervention. In conclusion, both groups had a similar pattern of modifiable risk factors 
suggesting that intensive lifestyle intervention is appropriate and necessary in all hypertensives 
even if medication is not indicated immediately. 
 
The two studies were done separately and the small numbers, particularly in Study One make it 
difficult to link the findings. Nonetheless, the borderline hypertensives had similar cardiovascular 
risk profiles and risk factors to the confirmed hypertensives (Study Two) and there was some 
evidence of vascular damage in the form of subclinical peripheral neuropathy (Study One) in the 
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newly diagnosed unmedicated essential hypertensives, many of whom (n=14) had a mean blood 
pressure in the borderline range (140-159/90-99 mmHg). Taken together, this may suggest that 
earlier initiation of antihypertensive medications in borderline patients with low cardiovascular 
risk might be appropriate, especially if these patients are showing signs of early vascular damage 
in the form of subclinical peripheral neuropathy (a potential surrogate of TOD). However, due to 
the small sample size of this preliminary study, it is not possible to determine whether subclinical 
peripheral neuropathy was present across all grades of hypertension. Much larger studies would 
be needed to establish this. 
 
4.1.3 Study One-Limitations 
With regard to peripheral neuropathy in hypertension, the results (at least for vibration sensation 
in the feet), agree with a small number of previous studies. However, there are some limitations 
that should be considered. These limitations may be contributing to the lack of statistical 
significance between groups and the opposing findings for cooling thresholds in the hand and 
foot and warming thresholds in the hand. 
 
The main limitation of this study was the small sample size, which reduced the power to detect 
differences in thresholds between the two groups. ANCOVA was only powered to detect a large 
effect size and for all sensory thresholds the effect size was either small or medium. 
Consequently, the results can only be regarded as preliminary. Furthermore, the hypertensive and 
normotensive groups were not matched for confounding variables such as age, sex, weight or 
BMI. The mean age of the hypertensive and normotensive groups were 36 years and 32 years 
respectively. There were more men in the hypertensive group than women (12, 8) and more 
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women in the normotensive group than men (16, 9), the mean weight of the hypertensive and 
normotensive groups were 69kg and 67kg respectively and the mean BMI of the hypertensive 
and normotensive groups were 29kg/m
2
 and 23.5 kg/m
2
 respectively. Although differences in 
age, sex and BMI were accounted for in the analyses and group differences for age and sex were 
not significant, statistical adjustment may not fully address the potential confounding effects of 
these variables in this study, thus it is always preferable to match study groups for confounding 
variables when possible.
135
 
 
Patients had varying durations of hypertension, which may be having an effect on presence or 
severity of neuropathy. Diabetic sensory neuropathy has been found to be independently 
associated with duration of hypertension.
78
 Conversely, hypoalgesia is evident even after acute 
increases in blood pressure in spontaneously hypertensive rats.
107
 
 
Over half (65%) of the hypertensive patients had a cardiovascular risk profile compatible with 
metabolic syndrome i.e. BMI >30 kg/m
2
 plus raised triglycerides, reduced HDL cholesterol 
and/or raised fasting plasma glucose. It is therefore difficult to ascertain, which risk factor(s) (if 
any) contributed to the sensory loss observed in the hypertensive group. 
 
Many factors influence sensory detection thresholds. As well as sex, age and body location and 
possibly blood pressure, variability of threshold may be explained by differences in thickness of 
tissue overlying receptor, skin temperature, spacial distribution of receptors or impulse 
transmission, none of which were accounted for in the current study.
117
 Central processing can 
also influence sensory detection threshold. Quantitative sensory testing cannot distinguish 
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between peripheral nerve damage and central nervous system (CNS) damage therefore this is 
another limitation. However, participants were not selected to take part if they had any condition 
predisposing to peripheral neuropathy, including CNS damage. Another limitation of QST is that 
it is not very effective at accounting for large variations in heat and pain sensitivity among 
individuals and although it can detect changes in sensory thresholds it does not provide any clues 
to the reasons for these changes such as axonal loss/demyelination. Sensory action potential 
amplitudes and sensory nerve conduction velocities would provide this additional information. 
 
Finally, although Spearman‟s correlation showed significant differences, this statistical test is not 
as accurate hierarchical linear regression analysis, which can account for confounding variables. 
Overall, concrete conclusions regarding hypertension and peripheral neuropathy cannot be drawn 
from this study. Further studies are needed in order to expand on these exciting but preliminary 
findings. 
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4.1.4 Study One-Recommendations for Future Research 
In light of these limitations, future studies would recruit more participants in order to achieve 
more significant results. Hypertensives would be categorised into those with Grade 1 (borderline) 
hypertension and those with Grade 2 hypertension, in order to see whether subclinical peripheral 
neuropathy is present across all grades of hypertension. The hypertensive and normotensive 
groups would be matched for age, sex, weight and BMI. If future research finds more established 
differences between hypertensives and normotensives, subsequent research might involve 
investigating mechanisms underlying these differences, using skin biopsies. Further studies might 
follow-up the hypertensive group, after the initiation of antihypertensive medication in any 
confirmed hypertensives (BP ≥160/100 mmHg), to see whether antihypertensive medications 
delay or prevent the onset of subclinical peripheral neuropathy or indeed prevent or delay its 
progression. Further studies might also follow up any borderline hypertensives (SBP 140-159 
and/or DBP 90-99 mmHg) to observe whether peripheral neuropathy worsens as their blood 
pressure rises. The management of hypertension might then be tailored to prevent or treat 
subclinical peripheral neuropathy as well as hypertension. In addition, future findings may be 
used to validate the use of antihypertensive drugs to prevent or treat other forms of neuropathy 
including diabetic neuropathy. Future studies should include metabolic syndrome in the exclusion 
criteria and carry out ambulatory blood pressure measurements on all participants, as well as 
sensory nerve conduction velocities and sensory action potentials to investigate the type of 
peripheral nerve damage e.g. demyelination and/or axonal damage. Future studies should also 
endeavor to adequately control for variations in skin temperature and perform hierarchical linear 
regression analyses in addition to Spearman‟s correlation in order to account for confounding 
variables. 
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4.1.5 Study Two-Limitations and Recommended Future Directions  
The main limitations of this study were the unbalanced numbers of patients in the confirmed and 
borderline group and the fact that outcome data was not available from the database. Future 
research might therefore follow-up all confirmed hypertensive and borderline hypertensive 
patients to investigate outcomes, in terms of blood pressure and cardiovascular events, using 
medical notes. 
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4.2 Conclusions  
The results of Study One demonstrated some evidence of subclinical peripheral neuropathy, in 
the form of reduced vibration sensation in the feet of patients with newly diagnosed unmedicated 
essential hypertension. However, due to the small sample size it was not possible to determine 
whether this finding was true across all grades of hypertension. Interrogation of the Hypertension 
Database revealed that unmedicated borderline hypertensives have similar cardiovascular risk 
profiles and similar modifiable cardiovascular risk factors to their confirmed hypertensive 
counterparts, suggesting that borderline patients necessitate intensive lifestyle advice at the very 
least.  
 
If the preliminary findings of Study One were replicated across all grades of hypertension in a 
much larger sample, this, in conjunction with the findings of Study Two may indicate the need 
for antihypertensive medications in borderline hypertensives, at otherwise low cardiovascular 
risk, who currently only receive lifestyle advice.  
 
If we assume the hypertensive patients from Study One had subclinical peripheral neuropathy, 
this might be due to metabolic syndrome, differences in age, sex, weight and/or BMI rather than 
BP alone. As a result of this and because of the many limitations in this preliminary study much 
further research is needed to expand on these promising early findings, prove their significance 
across all grades of hypertension, and determine underlying mechanisms before any definitive 
conclusions are reached, which may then ultimately be applied to clinical medicine. 
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APPENDICES 
Appendix A. Independent-Samples T Test. Unadjusted Mean (SD), Electrolyte Values of the Confirmed Hypertensive and 
Borderline Hypertensive Group as well as the Degrees of Freedom, t-Values and Statistical Significance Level of the Group Effects  
Variable Mean (SD) 
Confirmed 
HT’s 
Mean (SD) 
Borderline 
HT’s 
F Sig. t 
 
df Sig.     
(2-tailed) 
Mean 
Difference 
Standard 
Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Sodium 141.24 (2.53) 140.40 (5.38) 0.04 0.84 -1.33 231 0.18 -0.83 0.62 -2.06 0.40 
Potassium 4.24 (.35) 4.20 (.34) 0.08 0.78 -0.99 231 0.32 -0.05 0.05 -0.14 0.05 
Urea 5.25 (1.23) 4.70 (.96) 4.73 0.03* -3.51 140.84 <0.001** -0.54 0.16 -0.85 -0.24 
Creatinine 94.13 (13.63) 93.15 (15.13) 1.38 0.24 -0.49 231 0.63 -0.98 2.0 -4.92 2.96 
Total Cholesterol 5.19 (1.06) 5.20 (1.00) 0.12 0.12 0.11 234 0.91 0.02 0.14 -0.26 0.29 
HDL Cholesterol 1.55 (.51) 1.53 (.45) 1.0 0.99 -0.34 224 0.73 -0.02 0.07 -0.15 0.11 
Triglycerides 1.69 (.96) 1.52 (1.13) 0.03 0.03* -1.15 231 0.25 -0.17 0.15 -0.46 0.12 
GGT 34.78 (26.89) 37.67 (41.01) 2.25 2.25 0.58 228 0.57 2.89 5.02 -7.00 12.78 
Calcium 2.31 (.10) 2.32 (.10) 0.44 0.44 0.07 229 0.95 0.00 0.01 -0.03 0.03 
Glucose 5.44 (1.28) 5.07 (.89) 5.47 5.47 -2.35 126.16 0.02* -0.37 0.16 -0.68 -0.06 
Urate 322.68 (81.54) 324.80 (92.79) 2.25 2.25 0.17 227 0.86 2.12 12.26 -22.04 26.28 
*=significant group difference at 0.05 level  **=significant difference at 0.001 level 
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Appendix B. Independent-Samples T Test. Unadjusted Mean (SD), AASI, 10 year Coronary Risk and 10 year CVD Risk for the 
Confirmed Hypertensive and Borderline Hypertensive Group as well as the Degrees of Freedom, t-Values and Statistical Significance 
Levels of the Group Effects   
Variable Mean (SD) 
Confirmed        
HT’s 
Mean (SD) 
Borderline 
HT’s 
F Sig. t 
 
df Sig. 
(2-tailed) 
Mean 
Difference 
SE 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
AASI 0.39 (0.16) 0.31 (0.16) 0.51 0.48 -3.85 214 <0.001** -.086 0.02 -0.13 -0.04 
10 Year Coronary Risk 9.35 (8.14) 5.4 (6.21) 2.29 0.13 -4.04 222 <0.001** -3.91 0.969 -5.82 -2.00 
10 Year CDV Risk 17.8 (13.15) 9.38 (10.19) 4.42 0.04* -5.01 134.91 <0.001** -8.47 1.69 -11.82 -5.12 
*=significant group difference at 0.05 level  **=significant difference at 0.001 level 
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Appendix C. Presentations, Posters and Abstracts Arising From This Thesis 
 
Presentations 
Branch RL. Peripheral Neuropathy In Hypertension. Clinical Pharmacology Colloquium. 14
th
 
Nov 2009  
 
Posters 
Branch RL. Evidence of Peripheral Neuropathy in Unmedicated Hypertensives. British 
Pharmacological Society Winter Meeting. 2009 
 
Abstracts 
Branch R, Ali S, Ring C, Winer J, Martin U. Evidence of Peripheral Neuropathy in Unmedicated 
Hypertensives. Br J Clin Pharmacol. 2010; 70(2): 293 
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